Form **990**

Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

▶ Do not enter social security numbers on this form as it may be made public.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017

Open to Public Inspection

A For the 2017 calendar year, or tax year beginning APR 1, 2017 and ending MAR 31, 2018

B Check if applicable:
- ☐ Address change
- ☐ Name change
- ☐ Initial return
- ☐ Final return/ terminated
- ☐ Amended return
- ☐ Application pending

C Name of organization
BRIGHTFOCUS FOUNDATION

Doing business as

Number and street (or P.O. box if mail is not delivered to street address) Room/suite
22512 GATEWAY CENTER DRIVE

City or town, state or province, country, and ZIP or foreign postal code
CLARKSBURG, MD 20871

F Name and address of principal officer: STACY PAGOS HALLER
SAME AS C ABOVE

D Employer identification number
23-7337229

E Telephone number
(301) 948-3244

G Gross receipts $ 47,461,052.

H(a) Is this a group return for subordinates? ☐ Yes ☒ No

H(b) Are all subordinates included? ☐ Yes ☐ No
If "No," attach a list. (see instructions)

H(c) Group exemption number ▶

I Tax-exempt status: ☒ 501(c)(3) ☐ 501(c) ( ) ◀ (insert no.) ☐ 4947(a)(1) or ☐ 527

J Website: ▶ WWW.BRIGHTFOCUS.ORG

K Form of organization: ☒ Corporation ☐ Trust ☐ Association ☐ Other ▶

L Year of formation: 1973 **M** State of legal domicile: DC

Part I Summary

Activities & Governance	1 Briefly describe the organization's mission or most significant activities: BRIGHTFOCUS FOUNDATION SEEKS TO SAVE MIND AND SIGHT.		
	2 Check this box ▶ ☐ if the organization discontinued its operations or disposed of more than 25% of its net assets.		
	3 Number of voting members of the governing body (Part VI, line 1a)	3	15
	4 Number of independent voting members of the governing body (Part VI, line 1b)	4	15
	5 Total number of individuals employed in calendar year 2017 (Part V, line 2a)	5	57
	6 Total number of volunteers (estimate if necessary)	6	60
	7a Total unrelated business revenue from Part VIII, column (C), line 12	7a	0.
	b Net unrelated business taxable income from Form 990-T, line 34	7b	0.

		Prior Year	Current Year
Revenue	8 Contributions and grants (Part VIII, line 1h)	30,692,507.	32,362,197.
	9 Program service revenue (Part VIII, line 2g)	0.	0.
	10 Investment income (Part VIII, column (A), lines 3, 4, and 7d)	1,443,912.	1,854,269.
	11 Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	563,670.	688,039.
	12 Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	32,700,089.	34,904,505.
Expenses	13 Grants and similar amounts paid (Part IX, column (A), lines 1-3)	13,366,099.	13,475,744.
	14 Benefits paid to or for members (Part IX, column (A), line 4)	0.	0.
	15 Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	4,668,167.	4,985,215.
	16a Professional fundraising fees (Part IX, column (A), line 11e)	525,378.	636,451.
	b Total fundraising expenses (Part IX, column (D), line 25) ▶ 7,064,323.		
	17 Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	15,081,756.	16,718,081.
	18 Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	33,641,400.	35,815,491.
	19 Revenue less expenses. Subtract line 18 from line 12	-941,311.	-910,986.

		Beginning of Current Year	End of Year
Net Assets or Fund Balances	20 Total assets (Part X, line 16)	50,937,791.	52,594,473.
	21 Total liabilities (Part X, line 26)	19,242,456.	20,725,981.
	22 Net assets or fund balances. Subtract line 21 from line 20	31,695,335.	31,868,492.

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here

▶ Signature of officer — Date 08/01/18

▶ STACY PAGOS HALLER, PRESIDENT/CEO
Type or print name and title

Paid Preparer Use Only

Print/Type preparer's name: FRANK H. SMITH	Preparer's signature: Frank H. Smith	Date: 08/01/18	Check ☐ if self-employed	PTIN: P00639053
Firm's name ▶ RAFFA, P.C.			Firm's EIN ▶ 52-1511275	
Firm's address ▶ 1899 L STREET, NW, SUITE 850 WASHINGTON, DC 20036			Phone no. (202) 822-5000	

May the IRS discuss this return with the preparer shown above? (see instructions) ☒ Yes ☐ No

SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT CONTINUATION

*** ELECTRONICALLY FILED ON 08/01/2018 ***

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III ☐

1 Briefly describe the organization's mission:
BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) DRIVES INNOVATIVE RESEARCH WORLDWIDE AND PROMOTES AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION AND GLAUCOMA. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? ☐ Yes ☒ No
If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? ☐ Yes ☒ No
If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses $ 17,302,136. including grants of $ 9,257,024.) (Revenue $)
ALZHEIMER'S DISEASE RESEARCH (ADR) - BRIGHTFOCUS' ADR PROGRAM FUNDS RESEARCH FOCUSED ON UNDERSTANDING ALZHEIMER'S DISEASE'S CAUSES, ITS EARLY DETECTION, AND TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE.

SINCE INCEPTION, BRIGHTFOCUS HAS CONTRIBUTED MORE THAN $118 MILLION TO THE CONQUERING OF ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDED MARCH 31, 2018, ADR FUNDED 39 NEW RESEARCH AWARDS TOTALING $9,117,024.

4b (Code:) (Expenses $ 5,229,453. including grants of $ 2,319,410.) (Revenue $)
MACULAR DEGENERATION RESEARCH (MDR)- A PROGRAM OF BRIGHTFOCUS, HAS AWARDED MORE THAN $26 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS FOR THE DISEASE, UNDERSTANDING ITS CAUSES AND PROGRESSION, DRUG THERAPIES, AND NEW SCREENING TECHNIQUES.

DURING THE FISCAL YEAR ENDING MARCH 31, 2018, MDR AWARDED $2,080,000 IN PEER-REVIEWED GRANT AWARDS TO 13 NEW RESEARCH PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

4c (Code:) (Expenses $ 2,676,044. including grants of $ 1,899,310.) (Revenue $)
NATIONAL GLAUCOMA RESEARCH (NGR)- BRIGHTFOCUS' NGR PROGRAM HAS AWARDED MORE THAN $32 MILLION WORLDWIDE FOR THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS BEEN FOCUSED ON THE EYE-BRAIN CONNECTION, THE MECHANISMS FOR PRESSURE BUILDUP IN THE EYE, PREVENTING DAMAGE TO THE OPTIC NERVE, AND UNDERSTANDING THE ROLE GENES PLAY IN ORDER TO DEVELOP EARLY GLAUCOMA SCREENING AND TARGETED TREATMENTS, AMONGST OTHER INNOVATIVE PURSUITS.

NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

4d Other program services (Describe in Schedule O.)
(Expenses $ including grants of $) (Revenue $)

4e Total program service expenses ▶ 25,207,633.

Part IV Checklist of Required Schedules

			Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? *If "Yes," complete Schedule A*	1	X	
2	Is the organization required to complete *Schedule B, Schedule of Contributors*?	2		X
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? *If "Yes," complete Schedule C, Part I*	3		X
4	**Section 501(c)(3) organizations.** Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year? *If "Yes," complete Schedule C, Part II*	4	X	
5	Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Revenue Procedure 98-19? *If "Yes," complete Schedule C, Part III*	5		X
6	Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? *If "Yes," complete Schedule D, Part I*	6		X
7	Did the organization receive or hold a conservation easement, including easements to preserve open space, the environment, historic land areas, or historic structures? *If "Yes," complete Schedule D, Part II*	7		X
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? *If "Yes," complete Schedule D, Part III*	8		X
9	Did the organization report an amount in Part X, line 21, for escrow or custodial account liability, serve as a custodian for amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services? *If "Yes," complete Schedule D, Part IV*	9		X
10	Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi-endowments? *If "Yes," complete Schedule D, Part V*	10	X	
11	If the organization's answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable.			
a	Did the organization report an amount for land, buildings, and equipment in Part X, line 10? *If "Yes," complete Schedule D, Part VI*	11a	X	
b	Did the organization report an amount for investments - other securities in Part X, line 12 that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part VII*	11b	X	
c	Did the organization report an amount for investments - program related in Part X, line 13 that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part VIII*	11c		X
d	Did the organization report an amount for other assets in Part X, line 15 that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part IX*	11d		X
e	Did the organization report an amount for other liabilities in Part X, line 25? *If "Yes," complete Schedule D, Part X*	11e	X	
f	Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses the organization's liability for uncertain tax positions under FIN 48 (ASC 740)? *If "Yes," complete Schedule D, Part X*	11f	X	
12a	Did the organization obtain separate, independent audited financial statements for the tax year? *If "Yes," complete Schedule D, Parts XI and XII*	12a		X
b	Was the organization included in consolidated, independent audited financial statements for the tax year? *If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional*	12b	X	
13	Is the organization a school described in section 170(b)(1)(A)(ii)? *If "Yes," complete Schedule E*	13		X
14a	Did the organization maintain an office, employees, or agents outside of the United States?	14a		X
b	Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more? *If "Yes," complete Schedule F, Parts I and IV*	14b	X	
15	Did the organization report on Part IX, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization? *If "Yes," complete Schedule F, Parts II and IV*	15	X	
16	Did the organization report on Part IX, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals? *If "Yes," complete Schedule F, Parts III and IV*	16		X
17	Did the organization report a total of more than $15,000 of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? *If "Yes," complete Schedule G, Part I*	17	X	
18	Did the organization report more than $15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? *If "Yes," complete Schedule G, Part II*	18	X	
19	Did the organization report more than $15,000 of gross income from gaming activities on Part VIII, line 9a? *If "Yes," complete Schedule G, Part III*	19		X

Part IV Checklist of Required Schedules *(continued)*

			Yes	No
20a	Did the organization operate one or more hospital facilities? *If "Yes," complete Schedule H*	20a		X
b	If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?	20b		
21	Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? *If "Yes," complete Schedule I, Parts I and II*	21	X	
22	Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? *If "Yes," complete Schedule I, Parts I and III*	22		X
23	Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5 about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? *If "Yes," complete Schedule J*	23	X	
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002? *If "Yes," answer lines 24b through 24d and complete Schedule K. If "No", go to line 25a*	24a		X
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b		
c	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?	24c		
d	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d		
25a	**Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.** Did the organization engage in an excess benefit transaction with a disqualified person during the year? *If "Yes," complete Schedule L, Part I*	25a		X
b	Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? *If "Yes," complete Schedule L, Part I*	25b		X
26	Did the organization report any amount on Part X, line 5, 6, or 22 for receivables from or payables to any current or former officers, directors, trustees, key employees, highest compensated employees, or disqualified persons? *If "Yes," complete Schedule L, Part II*	26		X
27	Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity or family member of any of these persons? *If "Yes," complete Schedule L, Part III*	27		X
28	Was the organization a party to a business transaction with one of the following parties (see Schedule L, Part IV instructions for applicable filing thresholds, conditions, and exceptions):			
a	A current or former officer, director, trustee, or key employee? *If "Yes," complete Schedule L, Part IV*	28a		X
b	A family member of a current or former officer, director, trustee, or key employee? *If "Yes," complete Schedule L, Part IV*	28b		X
c	An entity of which a current or former officer, director, trustee, or key employee (or a family member thereof) was an officer, director, trustee, or direct or indirect owner? *If "Yes," complete Schedule L, Part IV*	28c		X
29	Did the organization receive more than $25,000 in non-cash contributions? *If "Yes," complete Schedule M*	29	X	
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? *If "Yes," complete Schedule M*	30		X
31	Did the organization liquidate, terminate, or dissolve and cease operations? *If "Yes," complete Schedule N, Part I*	31		X
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? *If "Yes," complete Schedule N, Part II*	32		X
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? *If "Yes," complete Schedule R, Part I*	33	X	
34	Was the organization related to any tax-exempt or taxable entity? *If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1*	34		X
35a	Did the organization have a controlled entity within the meaning of section 512(b)(13)?	35a		X
b	If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? *If "Yes," complete Schedule R, Part V, line 2*	35b		
36	**Section 501(c)(3) organizations.** Did the organization make any transfers to an exempt non-charitable related organization? *If "Yes," complete Schedule R, Part V, line 2*	36		X
37	Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? *If "Yes," complete Schedule R, Part VI*	37		X
38	Did the organization complete Schedule O and provide explanations in Schedule O for Part VI, lines 11b and 19? **Note.** All Form 990 filers are required to complete Schedule O	38	X	

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V ☐

				Yes	No
1a	Enter the number reported in Box 3 of Form 1096. Enter -0- if not applicable	1a	172		
b	Enter the number of Forms W-2G included in line 1a. Enter -0- if not applicable	1b	0		
c	Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?		1c	X	
2a	Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements, filed for the calendar year ending with or within the year covered by this return	2a	57		
b	If at least one is reported on line 2a, did the organization file all required federal employment tax returns?		2b	X	
	Note. If the sum of lines 1a and 2a is greater than 250, you may be required to *e-file* (see instructions)				
3a	Did the organization have unrelated business gross income of $1,000 or more during the year?		3a		X
b	If "Yes," has it filed a Form 990-T for this year? *If "No," to line 3b, provide an explanation in Schedule O*		3b		
4a	At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?		4a		X
b	If "Yes," enter the name of the foreign country: ▶				
	See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).				
5a	Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?		5a		X
b	Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?		5b		X
c	If "Yes," to line 5a or 5b, did the organization file Form 8886-T?		5c		
6a	Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?		6a		X
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?		6b		
7	**Organizations that may receive deductible contributions under section 170(c).**				
a	Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?		7a	X	
b	If "Yes," did the organization notify the donor of the value of the goods or services provided?		7b	X	
c	Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?		7c		X
d	If "Yes," indicate the number of Forms 8282 filed during the year	7d			
e	Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?		7e		X
f	Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?		7f		X
g	If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?		7g		
h	If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?		7h		
8	**Sponsoring organizations maintaining donor advised funds.** Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?		8		
9	**Sponsoring organizations maintaining donor advised funds.**				
a	Did the sponsoring organization make any taxable distributions under section 4966?		9a		
b	Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?		9b		
10	**Section 501(c)(7) organizations.** Enter:				
a	Initiation fees and capital contributions included on Part VIII, line 12	10a			
b	Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities	10b			
11	**Section 501(c)(12) organizations.** Enter:				
a	Gross income from members or shareholders	11a			
b	Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them.)	11b			
12a	**Section 4947(a)(1) non-exempt charitable trusts.** Is the organization filing Form 990 in lieu of Form 1041?		12a		
b	If "Yes," enter the amount of tax-exempt interest received or accrued during the year	12b			
13	**Section 501(c)(29) qualified nonprofit health insurance issuers.**				
a	Is the organization licensed to issue qualified health plans in more than one state?		13a		
	Note. See the instructions for additional information the organization must report on Schedule O.				
b	Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans	13b			
c	Enter the amount of reserves on hand	13c			
14a	Did the organization receive any payments for indoor tanning services during the tax year?		14a		X
b	If "Yes," has it filed a Form 720 to report these payments? *If "No," provide an explanation in Schedule O*		14b		

Part VI Governance, Management, and Disclosure *For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.*

Check if Schedule O contains a response or note to any line in this Part VI X

Section A. Governing Body and Management

				Yes	No
1a	Enter the number of voting members of the governing body at the end of the tax year	1a	15		
	If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.				
b	Enter the number of voting members included in line 1a, above, who are independent	1b	15		
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?	2			X
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors, or trustees, or key employees to a management company or other person?	3			X
4	Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?	4			X
5	Did the organization become aware during the year of a significant diversion of the organization's assets?	5			X
6	Did the organization have members or stockholders?	6			X
7a	Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?	7a			X
b	Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?	7b			X
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:				
a	The governing body?	8a		X	
b	Each committee with authority to act on behalf of the governing body?	8b		X	
9	Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? *If "Yes," provide the names and addresses in Schedule O*	9			X

Section B. Policies *(This Section B requests information about policies not required by the Internal Revenue Code.)*

			Yes	No
10a	Did the organization have local chapters, branches, or affiliates?	10a		X
b	If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?	10b		
11a	Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	11a	X	
b	Describe in Schedule O the process, if any, used by the organization to review this Form 990.			
12a	Did the organization have a written conflict of interest policy? *If "No," go to line 13*	12a	X	
b	Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	X	
c	Did the organization regularly and consistently monitor and enforce compliance with the policy? *If "Yes," describe in Schedule O how this was done*	12c	X	
13	Did the organization have a written whistleblower policy?	13	X	
14	Did the organization have a written document retention and destruction policy?	14	X	
15	Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?			
a	The organization's CEO, Executive Director, or top management official	15a	X	
b	Other officers or key employees of the organization	15b	X	
	If "Yes" to line 15a or 15b, describe the process in Schedule O (see instructions).			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?	16a		X
b	If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?	16b		

Section C. Disclosure

17 List the states with which a copy of this Form 990 is required to be filed ▶ AK, AL, AR, AZ, CA, CT, FL, GA, HI, IL, KS, KY

18 Section 6104 requires an organization to make its Forms 1023 (or 1024 if applicable), 990, and 990-T (Section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.

X Own website X Another's website X Upon request ☐ Other *(explain in Schedule O)*

19 Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.

20 State the name, address, and telephone number of the person who possesses the organization's books and records: ▶

DAVID F. MARKS, CPA, CMA - (301) 948-3244
22512 GATEWAY CENTER DRIVE, CLARKSBURG, MD 20871

Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

Check if Schedule O contains a response or note to any line in this Part VII ☐

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
- List all of the organization's **current** key employees, if any. See instructions for definition of "key employee."
- List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than $100,000 from the organization and any related organizations.
- List all of the organization's **former** officers, key employees, and highest compensated employees who received more than $100,000 of reportable compensation from the organization and any related organizations.
- List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than $10,000 of reportable compensation from the organization and any related organizations.

List persons in the following order: individual trustees or directors; institutional trustees; officers; key employees; highest compensated employees; and former such persons.

☐ Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) SCOTT RODGVILLE, CPA CHAIR	5.00	X		X				0.	0.	0.
(2) DIANE I. MARCELLO VICE CHAIR	3.00	X		X				0.	0.	0.
(3) NICHOLAS W. RAYMOND TREASURER	20.00	X		X				0.	0.	0.
(4) JUDITH F. LEE SECRETARY	4.00	X		X				0.	0.	0.
(5) CECILIA ARRADAZA DIRECTOR	2.00	X						0.	0.	0.
(6) MICHAEL H. BARNETT, ESQ. DIRECTOR	3.00	X						0.	0.	0.
(7) MADDY DYCHTWALD DIRECTOR	1.00	X						0.	0.	0.
(8) GRACE FRISONE DIRECTOR	6.00	X						0.	0.	0.
(9) JUNE KINOSHITA DIRECTOR	3.00	X						0.	0.	0.
(10) HENRY J. POWNALL, PHD DIRECTOR	1.00	X						0.	0.	0.
(11) BRIAN K. REGAN, PHD DIRECTOR	4.00	X						0.	0.	0.
(12) ELTJO (ED) R. SCHOONVELD DIRECTOR	3.00	X						0.	0.	0.
(13) PATRICIA M. STEWART DIRECTOR	3.00	X						0.	0.	0.
(14) JAN M. STOUFFER, PHD DIRECTOR	3.00	X						0.	0.	0.
(15) ETHAN TREESE DIRECTOR	3.00	X						0.	0.	0.
(16) STACY PAGOS HALLER PRESIDENT/CEO	55.00			X				395,786.	0.	77,821.
(17) NANCY LYNN SR. VP STRATEGIC PARTNERSHIPS	45.00				X			230,312.	0.	28,959.

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees *(continued)*

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(18) R. BRIAN ELDERTON SR. VP, DEVELOPMENT	45.00				X			223,015.	0.	38,279.
(19) DAVID F. MARKS, CPA, CMA VP, FINANCE & ADMINISTRATION	45.00				X			152,620.	0.	61,854.
(20) DIANE BOVENKAMP, PHD VP, SCIENTIFIC AFFAIRS	45.00				X			152,385.	0.	25,938.
(21) MICHAEL BUCKLEY VP, PUBLIC AFFAIRS	45.00					X		144,280.	0.	45,334.
1b Sub-total ▶								1,298,398.	0.	278,185.
c Total from continuation sheets to Part VII, Section A ▶								0.	0.	0.
d Total (add lines 1b and 1c) ▶								1,298,398.	0.	278,185.

2 Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization ▶ 6

		Yes	No
3	Did the organization list any **former** officer, director, or trustee, key employee, or highest compensated employee on line 1a? *If "Yes," complete Schedule J for such individual*		X
4	For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000? *If "Yes," complete Schedule J for such individual*	X	
5	Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? *If "Yes," complete Schedule J for such person*		X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
RKD GROUP 201 SUMMER STREET, HOLLISTON, MA 01746	PUBLIC AWARENESS CONSUL. & MATERIALS	6,820,948.
BEACONFIRE REDENGINE, 2300 CLARENDON BLVD., SUITE 925, ARLINGTON, VA 22201	ONLINE PUBLIC AWARENESS CONSULTING	329,932.
DATA MANAGEMENT, INC. 160 STONE STREET, STONEVILLE, NC 27048	DATABASE MANAGEMENT	207,039.
RAFFA, P.C. 1899 L STREET, NW, WASHINGTON, DC 20036	ACCOUNTING & HUMAN RESOURCES	138,675.
GLOBAL TECHNOLOGY SOLUTIONS, INC., 2977 STEWART LOOP, UNIT B, FORT MEADE, MD 20755	BUILDING & OFFICE SERVICES	136,262.

2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization ▶ 8

Part VIII Statement of Revenue

Check if Schedule O contains a response or note to any line in this Part VIII ☐

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512-514
Contributions, Gifts, Grants and Other Similar Amounts	1a Federated campaigns	1a	175,615.				
	b Membership dues	1b					
	c Fundraising events	1c	191,321.				
	d Related organizations	1d					
	e Government grants (contributions)	1e					
	f All other contributions, gifts, grants, and similar amounts not included above	1f	31995261.				
	g Noncash contributions included in lines 1a-1f: $ 180,229.						
	h **Total.** Add lines 1a-1f			32362197.			
Program Service Revenue		**Business Code**					
	2a						
	b						
	c						
	d						
	e						
	f All other program service revenue						
	g **Total.** Add lines 2a-2f						
Other Revenue	3 Investment income (including dividends, interest, and other similar amounts)			667,662.			667,662.
	4 Income from investment of tax-exempt bond proceeds						
	5 Royalties			338,375.			338,375.
		(i) Real	(ii) Personal				
	6a Gross rents	635,730.					
	b Less: rental expenses	67,471.					
	c Rental income or (loss)	568,259.					
	d Net rental income or (loss)			568,259.			568,259.
		(i) Securities	(ii) Other				
	7a Gross amount from sales of assets other than inventory	13430888					
	b Less: cost or other basis and sales expenses	12244281					
	c Gain or (loss)	1186607.					
	d Net gain or (loss)			1,186,607.			1186607.
	8a Gross income from fundraising events (not including $ 191,321. of contributions reported on line 1c). See Part IV, line 18	a	26,200.				
	b Less: direct expenses	b	244,795.				
	c Net income or (loss) from fundraising events			-218,595.			-218,595.
	9a Gross income from gaming activities. See Part IV, line 19	a					
	b Less: direct expenses	b					
	c Net income or (loss) from gaming activities						
	10a Gross sales of inventory, less returns and allowances	a					
	b Less: cost of goods sold	b					
	c Net income or (loss) from sales of inventory						
	Miscellaneous Revenue	**Business Code**					
	11a						
	b						
	c						
	d All other revenue						
	e **Total.** Add lines 11a-11d						
	12 **Total revenue.** See instructions.			34904505.	0.	0.	2542308.

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX ☐

	Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	11,669,727.	11,669,727.		
2	Grants and other assistance to domestic individuals. See Part IV, line 22				
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	1,806,017.	1,806,017.		
4	Benefits paid to or for members				
5	Compensation of current officers, directors, trustees, and key employees	1,343,698.	768,551.	311,892.	263,255.
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)				
7	Other salaries and wages	2,612,988.	1,444,536.	816,214.	352,238.
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	295,248.	163,222.	92,226.	39,800.
9	Other employee benefits	486,617.	269,016.	152,004.	65,597.
10	Payroll taxes	246,664.	136,363.	77,050.	33,251.
11	Fees for services (non-employees):				
a	Management				
b	Legal	120,505.	69,034.	51,471.	
c	Accounting	83,660.	37,995.	21,685.	23,980.
d	Lobbying				
e	Professional fundraising services. See Part IV, line 17	636,451.			636,451.
f	Investment management fees	254,466.		254,466.	
g	Other. (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Sch O.)	1,245,431.	1,042,223.	130,955.	72,253.
12	Advertising and promotion				
13	Office expenses	849,611.	391,563.	228,659.	229,389.
14	Information technology	673,705.	454,498.	142,641.	76,566.
15	Royalties				
16	Occupancy	335,125.	193,985.	106,760.	34,380.
17	Travel	256,342.	165,324.	60,529.	30,489.
18	Payments of travel or entertainment expenses for any federal, state, or local public officials				
19	Conferences, conventions, and meetings	184,654.	171,843.	8,520.	4,291.
20	Interest	11,560.	6,691.	3,683.	1,186.
21	Payments to affiliates				
22	Depreciation, depletion, and amortization	517,453.	294,333.	154,827.	68,293.
23	Insurance	96,036.	32,256.	56,101.	7,679.
24	Other expenses. Itemize expenses not covered above. (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)				
a	PUB. AWARENESS POSTAGE	5,569,686.	2,806,267.	427,395.	2,336,024.
b	PUB. AWARENESS PRINTING	3,520,850.	1,776,998.	258,494.	1,485,358.
c	PUB. AWARENESS COMP.	1,719,033.	860,516.	109,608.	748,909.
d	LIST RENTAL	1,279,964.	646,675.	78,355.	554,934.
e	All other expenses				
25	**Total functional expenses.** Add lines 1 through 24e	35,815,491.	25,207,633.	3,543,535.	7,064,323.
26	**Joint costs.** Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here ▶ [X] if following SOP 98-2 (ASC 958-720)	12,114,706.	5,672,353.	929,784.	5,512,569.

Part X Balance Sheet

Check if Schedule O contains a response or note to any line in this Part X ☐

			(A) Beginning of year		(B) End of year
Assets	1	Cash - non-interest-bearing	1,594,850.	1	2,635,346.
	2	Savings and temporary cash investments	326,842.	2	239,243.
	3	Pledges and grants receivable, net	5,847,688.	3	4,651,980.
	4	Accounts receivable, net		4	
	5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L		5	
	6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instr). Complete Part II of Sch L		6	
	7	Notes and loans receivable, net		7	
	8	Inventories for sale or use	39,584.	8	43,224.
	9	Prepaid expenses and deferred charges	321,683.	9	308,170.
	10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D — 10a: 11,984,567.			
	b	Less: accumulated depreciation — 10b: 3,991,974.	8,398,877.	10c	7,992,593.
	11	Investments - publicly traded securities	29,268,444.	11	31,354,433.
	12	Investments - other securities. See Part IV, line 11	4,593,490.	12	4,854,970.
	13	Investments - program-related. See Part IV, line 11		13	
	14	Intangible assets		14	
	15	Other assets. See Part IV, line 11	546,333.	15	514,514.
	16	**Total assets.** Add lines 1 through 15 (must equal line 34)	50,937,791.	16	52,594,473.
Liabilities	17	Accounts payable and accrued expenses	272,073.	17	338,902.
	18	Grants payable	17,420,470.	18	18,854,761.
	19	Deferred revenue	0.	19	109,250.
	20	Tax-exempt bond liabilities		20	
	21	Escrow or custodial account liability. Complete Part IV of Schedule D		21	
	22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified persons. Complete Part II of Schedule L		22	
	23	Secured mortgages and notes payable to unrelated third parties		23	
	24	Unsecured notes and loans payable to unrelated third parties		24	
	25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D	1,549,913.	25	1,423,068.
	26	**Total liabilities.** Add lines 17 through 25	19,242,456.	26	20,725,981.
Net Assets or Fund Balances		**Organizations that follow SFAS 117 (ASC 958), check here ▶ ☒ and complete lines 27 through 29, and lines 33 and 34.**			
	27	Unrestricted net assets	18,011,943.	27	19,576,833.
	28	Temporarily restricted net assets	13,593,392.	28	11,971,659.
	29	Permanently restricted net assets	90,000.	29	320,000.
		Organizations that do not follow SFAS 117 (ASC 958), check here ▶ ☐ and complete lines 30 through 34.			
	30	Capital stock or trust principal, or current funds		30	
	31	Paid-in or capital surplus, or land, building, or equipment fund		31	
	32	Retained earnings, endowment, accumulated income, or other funds		32	
	33	Total net assets or fund balances	31,695,335.	33	31,868,492.
	34	Total liabilities and net assets/fund balances	50,937,791.	34	52,594,473.

Form **990** (2017)

Part XI Reconciliation of Net Assets

Check if Schedule O contains a response or note to any line in this Part XI X

1	Total revenue (must equal Part VIII, column (A), line 12)	1	34,904,505.
2	Total expenses (must equal Part IX, column (A), line 25)	2	35,815,491.
3	Revenue less expenses. Subtract line 2 from line 1	3	-910,986.
4	Net assets or fund balances at beginning of year (must equal Part X, line 33, column (A))	4	31,695,335.
5	Net unrealized gains (losses) on investments	5	599,410.
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain in Schedule O)	9	484,733.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 33, column (B))	10	31,868,492.

Part XII Financial Statements and Reporting

Check if Schedule O contains a response or note to any line in this Part XII .....

			Yes	No
1	Accounting method used to prepare the Form 990: ☐ Cash ☒ Accrual ☐ Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain in Schedule O.			
2a	Were the organization's financial statements compiled or reviewed by an independent accountant? If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both: ☐ Separate basis ☐ Consolidated basis ☐ Both consolidated and separate basis	2a		X
b	Were the organization's financial statements audited by an independent accountant? If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both: ☐ Separate basis ☒ Consolidated basis ☐ Both consolidated and separate basis	2b	X	
c	If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.	2c	X	
3a	As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?	3a		X
b	If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits	3b		

SCHEDULE A (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.

▶ **Attach to Form 990 or Form 990-EZ.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

1 ☐ A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**

2 ☐ A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990 or 990-EZ).)

3 ☐ A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**

4 ☐ A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state: _____

5 ☐ An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)

6 ☐ A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**

7 ☒ An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)

8 ☐ A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)

9 ☐ An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions). Enter the name, city, and state of the college or university: _____

10 ☐ An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions - subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)

11 ☐ An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**

12 ☐ An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2).** See **section 509(a)(3).** Check the box in lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

a ☐ **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**

b ☐ **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**

c ☐ **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**

d ☐ **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**

e ☐ Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

f Enter the number of supported organizations .....

g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document? Yes	(iv) No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
Total						

Part II **Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)**

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")	25126233.	27946621.	29220730.	30692507.	32362197.	145348288
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 **Total.** Add lines 1 through 3	25126233.	27946621.	29220730.	30692507.	32362197.	145348288
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)						
6 **Public support.** Subtract line 5 from line 4.						145348288

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
7 Amounts from line 4	25126233.	27946621.	29220730.	30692507.	32362197.	145348288
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources	1539583.	1633842.	1578975.	1622675.	1641767.	8016842.
9 Net income from unrelated business activities, whether or not the business is regularly carried on						
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
11 **Total support.** Add lines 7 through 10						153365130

12 Gross receipts from related activities, etc. (see instructions) 12 51,200.

13 **First five years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ▶ ☐

Section C. Computation of Public Support Percentage

14 Public support percentage for 2017 (line 6, column (f) divided by line 11, column (f)) 14 94.77 %

15 Public support percentage from 2016 Schedule A, Part II, line 14 15 94.66 %

16a **33 1/3% support test - 2017.** If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☒

b **33 1/3% support test - 2016.** If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☐

17a **10% -facts-and-circumstances test - 2017.** If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and **stop here.** Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ▶ ☐

b **10% -facts-and-circumstances test - 2016.** If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and **stop here.** Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ▶ ☐

18 **Private foundation.** If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions ▶ ☐

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 **Total.** Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year						
c Add lines 7a and 7b						
8 **Public support.** (Subtract line 7c from line 6.)						

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
9 Amounts from line 6						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13 **Total support.** (Add lines 9, 10c, 11, and 12.)						

14 **First five years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ▶ ☐

Section C. Computation of Public Support Percentage

15 Public support percentage for 2017 (line 8, column (f) divided by line 13, column (f))	15	%
16 Public support percentage from 2016 Schedule A, Part III, line 15	16	%

Section D. Computation of Investment Income Percentage

17 Investment income percentage for **2017** (line 10c, column (f) divided by line 13, column (f))	17	%
18 Investment income percentage from **2016** Schedule A, Part III, line 17	18	%

19a 33 1/3% support tests - 2017. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☐

b 33 1/3% support tests - 2016. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☐

20 **Private foundation.** If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ▶ ☐

Part IV Supporting Organizations

(Complete only if you checked a box in line 12 on Part I. If you checked 12a of Part I, complete Sections A and B. If you checked 12b of Part I, complete Sections A and C. If you checked 12c of Part I, complete Sections A, D, and E. If you checked 12d of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

			Yes	No
1	Are all of the organization's supported organizations listed by name in the organization's governing documents? *If "No," describe in* **Part VI** *how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.*	1		
2	Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? *If "Yes," explain in* **Part VI** *how the organization determined that the supported organization was described in section 509(a)(1) or (2).*	2		
3a	Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? *If "Yes," answer (b) and (c) below.*	3a		
b	Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? *If "Yes," describe in* **Part VI** *when and how the organization made the determination.*	3b		
c	Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? *If "Yes," explain in* **Part VI** *what controls the organization put in place to ensure such use.*	3c		
4a	Was any supported organization not organized in the United States ("foreign supported organization")? *If "Yes," and if you checked 12a or 12b in Part I, answer (b) and (c) below.*	4a		
b	Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? *If "Yes," describe in* **Part VI** *how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.*	4b		
c	Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? *If "Yes," explain in* **Part VI** *what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.*	4c		
5a	Did the organization add, substitute, or remove any supported organizations during the tax year? *If "Yes," answer (b) and (c) below (if applicable). Also, provide detail in* **Part VI,** *including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).*	5a		
b	**Type I or Type II only.** Was any added or substituted supported organization part of a class already designated in the organization's organizing document?	5b		
c	**Substitutions only.** Was the substitution the result of an event beyond the organization's control?	5c		
6	Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? *If "Yes," provide detail in* **Part VI.**	6		
7	Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? *If "Yes," complete Part I of Schedule L (Form 990 or 990-EZ).*	7		
8	Did the organization make a loan to a disqualified person (as defined in section 4958) not described in line 7? *If "Yes," complete Part I of Schedule L (Form 990 or 990-EZ).*	8		
9a	Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? *If "Yes," provide detail in* **Part VI.**	9a		
b	Did one or more disqualified persons (as defined in line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? *If "Yes," provide detail in* **Part VI.**	9b		
c	Did a disqualified person (as defined in line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? *If "Yes," provide detail in* **Part VI.**	9c		
10a	Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? *If "Yes," answer 10b below.*	10a		
b	Did the organization have any excess business holdings in the tax year? *(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)*	10b		

Part IV Supporting Organizations *(continued)*

			Yes	No
11	Has the organization accepted a gift or contribution from any of the following persons?			
a	A person who directly or indirectly controls, either alone or together with persons described in (b) and (c) below, the governing body of a supported organization?	11a		
b	A family member of a person described in (a) above?	11b		
c	A 35% controlled entity of a person described in (a) or (b) above? *If "Yes" to a, b, or c, provide detail in* **Part VI.**	11c		

Section B. Type I Supporting Organizations

			Yes	No
1	Did the directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's directors or trustees at all times during the tax year? *If "No," describe in* **Part VI** *how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.*	1		
2	Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? *If "Yes," explain in* **Part VI** *how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised, or controlled the supporting organization.*	2		

Section C. Type II Supporting Organizations

			Yes	No
1	Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? *If "No," describe in* **Part VI** *how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).*	1		

Section D. All Type III Supporting Organizations

			Yes	No
1	Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?	1		
2	Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? *If "No," explain in* **Part VI** *how the organization maintained a close and continuous working relationship with the supported organization(s).*	2		
3	By reason of the relationship described in (2), did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? *If "Yes," describe in* **Part VI** *the role the organization's supported organizations played in this regard.*	3		

Section E. Type III Functionally Integrated Supporting Organizations

1 *Check the box next to the method that the organization used to satisfy the Integral Part Test during the yea* **(see instructions).**

a ☐ The organization satisfied the Activities Test. *Complete* **line 2** *below.*

b ☐ The organization is the parent of each of its supported organizations. *Complete* **line 3** *below.*

c ☐ The organization supported a governmental entity. *Describe in* **Part VI** *how you supported a government entity (see instructions).*

			Yes	No
2	Activities Test. **Answer (a) and (b) below.**			
a	Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? *If "Yes," then in* **Part VI identify those supported organizations and explain** *how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.*	2a		
b	Did the activities described in (a) constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? *If "Yes," explain in* **Part VI** *the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.*	2b		
3	Parent of Supported Organizations. **Answer (a) and (b) below.**			
a	Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? *Provide details in* **Part VI.**	3a		
b	Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? *If "Yes," describe in* **Part VI** *the role played by the organization in this regard.*	3b		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

1 ☐ Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI.) **See instructions.** All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1 Net short-term capital gain	1		
2 Recoveries of prior-year distributions	2		
3 Other gross income (see instructions)	3		
4 Add lines 1 through 3	4		
5 Depreciation and depletion	5		
6 Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6		
7 Other expenses (see instructions)	7		
8 **Adjusted Net Income** (subtract lines 5, 6, and 7 from line 4)	8		

Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1 Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):			
a Average monthly value of securities	1a		
b Average monthly cash balances	1b		
c Fair market value of other non-exempt-use assets	1c		
d **Total** (add lines 1a, 1b, and 1c)	1d		
e **Discount** claimed for blockage or other factors (explain in detail in **Part VI**):			
2 Acquisition indebtedness applicable to non-exempt-use assets	2		
3 Subtract line 2 from line 1d	3		
4 Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions)	4		
5 Net value of non-exempt-use assets (subtract line 4 from line 3)	5		
6 Multiply line 5 by .035	6		
7 Recoveries of prior-year distributions	7		
8 **Minimum Asset Amount** (add line 7 to line 6)	8		

Section C - Distributable Amount		Current Year
1 Adjusted net income for prior year (from Section A, line 8, Column A)	1	
2 Enter 85% of line 1	2	
3 Minimum asset amount for prior year (from Section B, line 8, Column A)	3	
4 Enter greater of line 2 or line 3	4	
5 Income tax imposed in prior year	5	
6 **Distributable Amount.** Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6	

7 ☐ Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions).

Part V **Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations** *(continued)*

Section D - Distributions		Current Year
1	Amounts paid to supported organizations to accomplish exempt purposes	
2	Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	
3	Administrative expenses paid to accomplish exempt purposes of supported organizations	
4	Amounts paid to acquire exempt-use assets	
5	Qualified set-aside amounts (prior IRS approval required)	
6	Other distributions (describe in **Part VI**). See instructions.	
7	**Total annual distributions.** Add lines 1 through 6.	
8	Distributions to attentive supported organizations to which the organization is responsive (provide details in **Part VI**). See instructions.	
9	Distributable amount for 2017 from Section C, line 6	
10	Line 8 amount divided by line 9 amount	

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2017	(iii) Distributable Amount for 2017
1	Distributable amount for 2017 from Section C, line 6			
2	Underdistributions, if any, for years prior to 2017 (reasonable cause required- explain in **Part VI**). See instructions.			
3	Excess distributions carryover, if any, to 2017			
a				
b	From 2013			
c	From 2014			
d	From 2015			
e	From 2016			
f	**Total** of lines 3a through e			
g	Applied to underdistributions of prior years			
h	Applied to 2017 distributable amount			
i	Carryover from 2012 not applied (see instructions)			
j	Remainder. Subtract lines 3g, 3h, and 3i from 3f.			
4	Distributions for 2017 from Section D, line 7: $			
a	Applied to underdistributions of prior years			
b	Applied to 2017 distributable amount			
c	Remainder. Subtract lines 4a and 4b from 4.			
5	Remaining underdistributions for years prior to 2017, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, explain in **Part VI.** See instructions.			
6	Remaining underdistributions for 2017. Subtract lines 3h and 4b from line 1. For result greater than zero, explain in **Part VI.** See instructions.			
7	**Excess distributions carryover to 2018.** Add lines 3j and 4c.			
8	Breakdown of line 7:			
a	Excess from 2013			
b	Excess from 2014			
c	Excess from 2015			
d	Excess from 2016			
e	Excess from 2017			

Part VI **Supplemental Information.** Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, and 3b; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions.)

SCHEDULE C (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

▶ **Complete if the organization is described below.** ▶ **Attach to Form 990 or Form 990-EZ.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2017

Open to Public Inspection

If the organization answered "Yes," on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then

- Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes," on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes," on Form 990, Part IV, line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.

1 Provide a description of the organization's direct and indirect political campaign activities in Part IV.

2 Political campaign activity expenditures ▶ $

3 Volunteer hours for political campaign activities

Part I-B Complete if the organization is exempt under section 501(c)(3).

1 Enter the amount of any excise tax incurred by the organization under section 4955 ▶ $

2 Enter the amount of any excise tax incurred by organization managers under section 4955 ▶ $

3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ☐ Yes ☐ No

4a Was a correction made? ☐ Yes ☐ No

b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

1 Enter the amount directly expended by the filing organization for section 527 exempt function activities ▶ $

2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ▶ $

3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b ▶ $

4 Did the filing organization file **Form 1120-POL** for this year? ☐ Yes ☐ No

5 Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

Part II-A **Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).**

A Check ▶ ☐ if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).

B Check ▶ ☐ if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)	(a) Filing organization's totals	(b) Affiliated group totals
1a Total lobbying expenditures to influence public opinion (grass roots lobbying)	0.	
b Total lobbying expenditures to influence a legislative body (direct lobbying)	0.	
c Total lobbying expenditures (add lines 1a and 1b)	0.	
d Other exempt purpose expenditures	35,179,040.	
e Total exempt purpose expenditures (add lines 1c and 1d)	35,179,040.	
f Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000.	

If the amount on line 1e, column (a) or (b) is:	The lobbying nontaxable amount is:
Not over $500,000	20% of the amount on line 1e.
Over $500,000 but not over $1,000,000	$100,000 plus 15% of the excess over $500,000.
Over $1,000,000 but not over $1,500,000	$175,000 plus 10% of the excess over $1,000,000.
Over $1,500,000 but not over $17,000,000	$225,000 plus 5% of the excess over $1,500,000.
Over $17,000,000	$1,000,000.

g Grassroots nontaxable amount (enter 25% of line 1f)	250,000.	
h Subtract line 1g from line 1a. If zero or less, enter -0-	0.	
i Subtract line 1f from line 1c. If zero or less, enter -0-	0.	

j If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ☐ Yes ☐ No

4-Year Averaging Period Under section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)

Lobbying Expenditures During 4-Year Averaging Period

Calendar year (or fiscal year beginning in)	(a) 2014	(b) 2015	(c) 2016	(d) 2017	(e) Total
2a Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
b Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000.
c Total lobbying expenditures					
d Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
e Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000.
f Grassroots lobbying expenditures					

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes," response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.	(a) Yes	(a) No	(b) Amount
1 During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:			
a Volunteers?			
b Paid staff or management (include compensation in expenses reported on lines 1c through 1i)?			
c Media advertisements?			
d Mailings to members, legislators, or the public?			
e Publications, or published or broadcast statements?			
f Grants to other organizations for lobbying purposes?			
g Direct contact with legislators, their staffs, government officials, or a legislative body?			
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means?			
i Other activities?			
j Total. Add lines 1c through 1i			
2a Did the activities in line 1 cause the organization to be not described in section 501(c)(3)?			
b If "Yes," enter the amount of any tax incurred under section 4912			
c If "Yes," enter the amount of any tax incurred by organization managers under section 4912			
d If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?			

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

			Yes	No
1	Were substantially all (90% or more) dues received nondeductible by members?	1		
2	Did the organization make only in-house lobbying expenditures of $2,000 or less?	2		
3	Did the organization agree to carry over lobbying and political campaign activity expenditures from the prior year?	3		

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No," OR (b) Part III-A, line 3, is answered "Yes."

1	Dues, assessments and similar amounts from members	1	
2	Section 162(e) nondeductible lobbying and political expenditures **(do not include amounts of political expenses for which the section 527(f) tax was paid).**		
a	Current year	2a	
b	Carryover from last year	2b	
c	Total	2c	
3	Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues	3	
4	If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year?	4	
5	Taxable amount of lobbying and political expenditures (see instructions)	5	

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions); and Part II-B, line 1. Also, complete this part for any additional information.

SCHEDULE D (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year		
2	Aggregate value of contributions to (during year)		
3	Aggregate value of grants from (during year)		
4	Aggregate value at end of year		

5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control? ☐ Yes ☐ No

6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ☐ Yes ☐ No

Part II Conservation Easements. Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply).
- ☐ Preservation of land for public use (e.g., recreation or education)
- ☐ Preservation of a historically important land area
- ☐ Protection of natural habitat
- ☐ Preservation of a certified historic structure
- ☐ Preservation of open space

2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.

		Held at the End of the Tax Year
a	Total number of conservation easements	2a
b	Total acreage restricted by conservation easements	2b
c	Number of conservation easements on a certified historic structure included in (a)	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register	2d

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year ▶ _____

4 Number of states where property subject to conservation easement is located ▶ _____

5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ☐ Yes ☐ No

6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ _____

7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ $ _____

8 Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? ☐ Yes ☐ No

9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements.

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

1a If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

b If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i) Revenue included on Form 990, Part VIII, line 1 ▶ $ _____

(ii) Assets included in Form 990, Part X ▶ $ _____

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

a Revenue included on Form 990, Part VIII, line 1 ▶ $ _____

b Assets included in Form 990, Part X ▶ $ _____

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets *(continued)*

3 Using the organization's acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

a ☐ Public exhibition
b ☐ Scholarly research
c ☐ Preservation for future generations
d ☐ Loan or exchange programs
e ☐ Other

4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.

5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? ☐ Yes ☐ No

Part IV Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

1a Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII and complete the following table:

		Amount
c Beginning balance	1c	
d Additions during the year	1d	
e Distributions during the year	1e	
f Ending balance	1f	

2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided on Part XIII ☐

Part V Endowment Funds. Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	90,000.	90,000.	90,000.	90,000.	90,000.
b Contributions	234,806.	4,332.	4,344.	4,257.	3,933.
c Net investment earnings, gains, and losses	10,000.				
d Grants or scholarships					
e Other expenditures for facilities and programs	14,806.	4,332.	4,344.	4,257.	3,933.
f Administrative expenses					
g End of year balance	320,000.	90,000.	90,000.	90,000.	90,000.

2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

a Board designated or quasi-endowment ▶ .00 %
b Permanent endowment ▶ 100.00 %
c Temporarily restricted endowment ▶ .00 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by:

		Yes	No
(i) unrelated organizations	3a(i)	X	
(ii) related organizations	3a(ii)		X
b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R?	3b		

4 Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI Land, Buildings, and Equipment.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land	2,800,000.	1,147,363.		3,947,363.
b Buildings	1,629,400.	5,025,641.	2,934,539.	3,720,502.
c Leasehold improvements				
d Equipment		1,188,310.	880,181.	308,129.
e Other		193,853.	177,254.	16,599.
Total. Add lines 1a through 1e. *(Column (d) must equal Form 990, Part X, column (B), line 10c.)* ▶				7,992,593.

Part VII Investments - Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely-held equity interests		
(3) Other		
(A) ALTERNATIVE INVESTMENTS -		
(B) HEDGE FUND	4,854,970.	END-OF-YEAR MARKET VALUE
(C)		
(D)		
(E)		
(F)		
(G)		
(H)		
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 12.) ▶	4,854,970.	

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 13.) ▶		

Part IX Other Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. *(Column (b) must equal Form 990, Part X, col. (B) line 15.)* ▶	

Part X Other Liabilities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2) CHARITABLE GIFT ANNUITIES	1,181,420.
(3) RENTAL DEPOSITS	80,000.
(4) CAPITAL LEASE OBLIGATIONS	161,648.
(5)	
(6)	
(7)	
(8)	
(9)	
Total. *(Column (b) must equal Form 990, Part X, col. (B) line 25.)* ▶	1,423,068.

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII [X]

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total revenue, gains, and other support per audited financial statements			1	49,342,409.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:				
a	Net unrealized gains (losses) on investments	2a	599,410.		
b	Donated services and use of facilities	2b	13,658,057.		
c	Recoveries of prior year grants	2c	361,983.		
d	Other (Describe in Part XIII.)	2d	31,141.		
e	Add lines 2a through 2d			2e	14,650,591.
3	Subtract line 2e from line 1			3	34,691,818.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	254,466.		
b	Other (Describe in Part XIII.)	4b	-41,779.		
c	Add lines 4a and 4b			4c	212,687.
5	Total revenue. Add lines 3 and 4c. *(This must equal Form 990, Part I, line 12.)*			5	34,904,505.

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total expenses and losses per audited financial statements			1	49,169,252.
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:				
a	Donated services and use of facilities	2a	13,658,057.		
b	Prior year adjustments	2b			
c	Other losses	2c			
d	Other (Describe in Part XIII.)	2d	31,141.		
e	Add lines 2a through 2d			2e	13,689,198.
3	Subtract line 2e from line 1			3	35,480,054.
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	254,466.		
b	Other (Describe in Part XIII.)	4b	80,971.		
c	Add lines 4a and 4b			4c	335,437.
5	Total expenses. Add lines 3 and 4c. *(This must equal Form 990, Part I, line 18.)*			5	35,815,491.

Part XIII Supplemental Information.

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

PART V, LINE 4:

THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.

PART X, LINE 2:

BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2018, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.

PART XI, LINE 2D - OTHER ADJUSTMENTS:

Part XIII Supplemental Information *(continued)*

SPECIAL EVENT EXPENSE	31,141.

PART XI, LINE 4B - OTHER ADJUSTMENTS:

DEPRECIATION ON RENTAL PROPERTY	-41,779.

PART XII, LINE 2D - OTHER ADJUSTMENTS:

SPECIAL EVENT EXPENSE	31,141.

PART XII, LINE 4B - OTHER ADJUSTMENTS:

DEPRECIATION ON RENTAL PROPERTY	-41,779.
CHANGE IN PRESENT VALUE OF GRANTS	122,750.
TOTAL TO SCHEDULE D, PART XII, LINE 4B	80,971.

SCHEDULE F (Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15, or 16.

▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

1 **For grantmakers.** Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ..... [X] Yes [ ] No

2 **For grantmakers.** Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.

3 Activities per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in the region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
EUROPE (INCLUDING ICELAND & GREENLAND)	0	0	GRANTMAKING		310,000.
NORTH AMERICA	0	0	GRANTMAKING		300,000.
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		1,196,017.
3 a Sub-total	0	0			1,806,017.
b Total from continuation sheets to Part I	0	0			0.
c **Totals** (add lines 3a and 3b)	0	0			1,806,017.

LHA **For Paperwork Reduction Act Notice, see the Instructions for Form 990.** **Schedule F (Form 990) 2017**

732071 10-06-17

Part II **Grants and Other Assistance to Organizations or Entities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	ALZHEIMER'S DISEASE RESEARCH BY YIM LUI CAROL CHEUNG, PHD, ENTITLED:(A2018093S)	300,000.	WIRE	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY SAIMA HILAL, PHD, ENTITLED: (A2018165F)	150,000.	WIRE	0.		
		EAST ASIA AND THE PACIFIC	AD RESEARCH BY STEPHANIE RAINEY-SMITH, PHD, ENTITLED: (A2018402F)	149,998.	WIRE	0.		
		EAST ASIA AND THE PACIFIC	ALZHEIMER'S DISEASE RESEARCH BY BRETT COLLINS, PHD, ENTITLED: (A2018667S)	191,034.	WIRE	0.		
		NORTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY SANJEEV KUMAR, MD, FRCPC, ENTITLED: (A2018667S)	300,000.	WIRE	0.		
		EAST ASIA AND THE PACIFIC	ALZHEIMER'S DISEASE RESEARCH BY BENJAMIN HOGAN, PHD, ENTITLED: (A2018807S)	295,439.	WIRE	0.		
		EAST ASIA AND THE PACIFIC	NATIONAL GLAUCOMA RESEARCH BY YUAN LEI, PHD, ENTITLED: (G2018112)	99,546.	WIRE	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	MD DISEASE RESEARCH BY FLORIAN SENNLAUB, MD, PHD, ENTITLED: (M2018096)	160,000.	WIRE	0.		

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter ▶ 9

3 Enter total number of other organizations or entities ▶ 0

Schedule F (Form 990) 2017

See Schedule O for continuation of Grant Purpose, item (d)

COPY

Part II **Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States.** (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	MACULAR DEGENERATION RESEARCH BY CHI LUU, PHD, ENTITLED: (M2018144)	160,000.	WIRE	0.		

See Schedule O for continuation of Grant Purpose, item (d)

Part III **Grants and Other Assistance to Individuals Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

COPY

Part IV Foreign Forms

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)*	☐ Yes	☒ No
2	Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990)*	☐ Yes	☒ No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect To Certain Foreign Corporations (see Instructions for Form 5471)*	☒ Yes	☐ No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see Instructions for Form 8621)*	☐ Yes	☒ No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see Instructions for Form 8865)*	☐ Yes	☒ No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990)*	☐ Yes	☒ No

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE IN MOLECULAR BIOLOGY, CELL BIOLOGY, BIOCHEMISTRY, IMAGING AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE BOARD OF DIRECTORS SCIENTIFIC AFFAIRS COMMITTEE. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CITATION ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO A STATISTICAL SAMPLE OF WORKS SUPPORTED BY EITHER THE US FEDERAL GVERNMENT OR THAT OF OTHER FUNDING AGENCIES. BRIGHTFOCUS-SUPPORTED PUBLICATIONS ARE CONSISTENTLY CITED AT NEARLY TWICE THE FREQUENCY OF ANY OTHER COMPARISON GROUP. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES 2.2 ADDITIONAL GRANTS FOR PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT. THESE COME AT VALUES NEARLY 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGHOUT OUR WEBSITE AND WITHIN THE FINAL SCIENTIFIC PROGRESS REPORT, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO WE MAY ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 3:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

SCHEDULE G (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding Fundraising or Gaming Activities

Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to *www.irs.gov/Form990* for the latest instructions.

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

Part I Fundraising Activities. Complete if the organization answered "Yes" on Form 990, Part IV, line 17. Form 990-EZ filers are not required to complete this part.

1 Indicate whether the organization raised funds through any of the following activities. Check all that apply.

- a [X] Mail solicitations
- b [X] Internet and email solicitations
- c [ ] Phone solicitations
- d [X] In-person solicitations
- e [X] Solicitation of non-government grants
- f [ ] Solicitation of government grants
- g [X] Special fundraising events

2 a Did the organization have a written or oral agreement with any individual (including officers, directors, trustees, or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services? [X] Yes [ ] No

b If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	(ii) Activity	(iii) Did fundraiser have custody or control of contributions? Yes	(iii) No	(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
RKD GROUP - 201 SUMMER ST., HOLLISTON, MA 07146	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	24,286,994.	391,845.	23,895,149.
BEACONFIRE REDENGINE - 2300 CLARENDON BLVD., STE. 925,	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	1,390,161.	244,606.	1,145,555.
Total ▶				25,677,155.	636,451.	25,040,704.

3 List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

AK,AL,AR,AZ,CA,CO,CT,DC,FL,GA,HI,IL,KS,KY,LA,MA,MD,ME,MI,MN,MO,MS,NC,ND,NH
NJ,NM,NV,NY,OH,OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

SEE PART IV FOR CONTINUATIONS

Part II Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 AN EVENING OF BRIGHTFOC (event type)	(b) Event #2 (event type)	(c) Other events NONE (total number)	(d) Total events (add col. (a) through col. (c))
Revenue	1 Gross receipts	217,521.			217,521.
	2 Less: Contributions	191,321.			191,321.
	3 Gross income (line 1 minus line 2)	26,200.			26,200.
Direct Expenses	4 Cash prizes				
	5 Noncash prizes				
	6 Rent/facility costs	22,171.			22,171.
	7 Food and beverages	76,768.			76,768.
	8 Entertainment	90,808.			90,808.
	9 Other direct expenses	55,048.			55,048.
	10 Direct expense summary. Add lines 4 through 9 in column (d) ▶				244,795.
	11 Net income summary. Subtract line 10 from line 3, column (d) ▶				-218,595.

Part III Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col. (a) through col. (c))
Revenue	1 Gross revenue				
Direct Expenses	2 Cash prizes				
	3 Noncash prizes				
	4 Rent/facility costs				
	5 Other direct expenses				
	6 Volunteer labor	☐ Yes ____ % ☐ No	☐ Yes ____ % ☐ No	☐ Yes ____ % ☐ No	
	7 Direct expense summary. Add lines 2 through 5 in column (d) ▶				
	8 Net gaming income summary. Subtract line 7 from line 1, column (d) ▶				

9 Enter the state(s) in which the organization conducts gaming activities: _____

a Is the organization licensed to conduct gaming activities in each of these states? ☐ Yes ☐ No

b If "No," explain: _____

10a Were any of the organization's gaming licenses revoked, suspended, or terminated during the tax year? ☐ Yes ☐ No

b If "Yes," explain: _____

11 Does the organization conduct gaming activities with nonmembers? ☐ Yes ☐ No

12 Is the organization a grantor, beneficiary or trustee of a trust, or a member of a partnership or other entity formed to administer charitable gaming? ☐ Yes ☐ No

13 Indicate the percentage of gaming activity conducted in:

a The organization's facility 13a %

b An outside facility 13b %

14 Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name ▶

Address ▶

15a Does the organization have a contract with a third party from whom the organization receives gaming revenue? ☐ Yes ☐ No

b If "Yes," enter the amount of gaming revenue received by the organization ▶ $ _____ and the amount of gaming revenue retained by the third party ▶ $ _____

c If "Yes," enter name and address of the third party:

Name ▶

Address ▶

16 Gaming manager information:

Name ▶

Gaming manager compensation ▶ $ _____

Description of services provided ▶

☐ Director/officer ☐ Employee ☐ Independent contractor

17 Mandatory distributions:

a Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? ☐ Yes ☐ No

b Enter the amount of distributions required under state law to be distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year ▶ $

Part IV **Supplemental Information.** Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

SCHEDULE G, PART I, LINE 2B, LIST OF TEN HIGHEST PAID FUNDRAISERS:

(I) NAME OF FUNDRAISER: BEACONFIRE REDENGINE

(I) ADDRESS OF FUNDRAISER:

2300 CLARENDON BLVD., STE. 925, ARLINGTON, VA 22201

PART I, LINE 2B, COLUMN (V):

IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS $915,948 PER YEAR OF WHICH

Part IV **Supplemental Information** *(continued)*

$524,103 HAS BEEN ALLOCATED UNDER PART XI, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.

SCHEDULE I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations, Governments, and Individuals in the United States

Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.

▶ **Attach to Form 990.**

▶ **Go to www.irs.gov/Form990 for the latest information.**

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I General Information on Grants and Assistance

1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ..... [X] Yes [ ] No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

1 (a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
NORTHWESTERN UNIVERSITY 303 E. CHICAGO AVENUE CHICAGO, IL 60611	36-2167817	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CONGCONG HE, PHD, ENTITLED: (A2018100S)
WASHINGTON UNIVERSITY ONE BROOKINGS DRIVE ST. LOUIS, MO 63110	43-0653611	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHAO WANG, PHD, ENTITLED: (A2018128F)
UNIVERSITY OF FLORIDA 207 GRINTER HALL GAINESVILLE, FL 32611	59-6002052	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CARA CROFT, PHD, ENTITLED: (A2018149F)
WASHINGTON UNIVERSITY ONE BROOKINGS DRIVE ST. LOUIS, MO 63110	43-0653611	501(C)(3)	298,335.	0.			ALZHEIMER'S DISEASE RESEARCH BY TIMOTHY MILLER, MD, PHD, ENTITLED: (A2018169S)
UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE - 1320 S. DIXIE HWY, SUITE 650 - MIAMI, FL 33136	59-0624458	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY HOLLY CUKIER, PHD, ENTITLED: (A2018197S)
WASHINGTON UNIVERSITY 425 S. EUCLID AVENUE ST. LOUIS, MO 63110	43-0653611	501(C)(3)	295,569.	0.			ALZHEIMER'S DISEASE RESEARCH BY JASON HASSENSTAB, PHD, ENTITLED: (A2018202S)

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ..... ▶ 41.

3 Enter total number of other organizations listed in the line 1 table ..... ▶ 1.

See Schedule O for continuation of Grant Purpose, item (h)

COPY

Part II Continuation of Grants and Other Assistance to Governments and Organizations in the United States (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE - LA JOLLA, CA 92037	95-6006144	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY GOONHO PARK, PHD, ENTITLED: (A2018212F)
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - ONE GUSTAVE L. LEVY PLACE - NEW YORK CITY, NY 10029	13-6171197	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOSEPH CASTELLANO, PHD, ENTITLED: (A2018213S)
SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE - 10901 NORTH TORREY PINES ROAD - LA JOLLA, CA 98103	51-0197108	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY YINGJUN ZHAO, PHD, ENTITLED: (A2018214F)
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - ONE GUSTAVE L. LEVY PLACE - NEW YORK CITY, NY 10029	13-6171197	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MICKAEL AUDRAIN, PHD, ENTITLED: (A2018253F)
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES - 10010 NORTH TORREY PINES ROAD - LA JOLLA, CA 92037	95-2160097	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY WEIWEI FAN, PHD, ENTITLED: (A2018325S)
WASHINGTON UNIVERSITY 660 S. EUCLID AVENUE ST. LOUIS, MO 63110	43-0653611	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CELESTE KARCH, PHD, ENTITLED: (A2018349S)
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 3333 CALIFORNIA STREET, SUITE 315 - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ALEX SMITH, PHD, ENTITLED: (A2018351S)
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON, TX 77030	74-1613878	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY WEI CAO, PHD, ENTITLED: (A2018377S)
UNIVERSITY OF CALIFORNIA, IRVINE 141 INNOVATION, SUITE 950 IRVINE, CA 92697	95-2226406	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOSHUA GRILL, PHD, ENTITLED: (A2018405S)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purpose, item (h)

COPY

Part II Continuation of Grants and Other Assistance to Governments and Organizations in the United States (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF MIAMI 1400 NW 10TH AVENUE MIAMI, FL 33136	59-0624458	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JEFFERY VANCE, MD, PHD, ENTITLED: (A2018425S)
UNIVERSITY OF SOUTHERN CALIFORNIA 3720 SOUTH FLOWER STREET LOS ANGELES, CA 90089	95-1642394	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SARA GALLANT, PHD, ENTITLED: (A2018449F)
THE RESEARCH FND. FOR SUNY ON BEHALF OF UNIV. AT BUFFALO - THE UB COMMONS, 520 LEE ENTRANCE, SUITE 211 - BUFFALO, NY 14228	14-1368361	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SHERMALI GUNAWARDENA, PHD, ENTITLED: (A2018509S)
UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE - 1320 S. DIXIE HWY, SUITE 650 - MIAMI, FL 33136	59-0624458	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY FARID RAJABLI, PHD, ENTITLED: (A2018556F)
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE - 4333 BROOKLYN AVENUE, NE - SEATTLE, WA 98195	91-6001534	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JESSICA YOUNG, PHD, ENTITLED: (A2018656S)
REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES - 10889 WILSHIRE BOULEVARD, SUITE 700 - LOS ANGELES, CA 90095	95-6006143	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DANIEL GESCHWIND, MD, PHD, ENTITLED: (A2018700S)
UNIVERSITY OF CALIFORNIA, IRVINE 141 INNOVATION, SUITE 950 IRVINE, CA 92697	95-2226406	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHARLES GLABE, PHD, ENTITLED: (A2018718S)
MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	150,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY NA ZHAO, MD, PHD, ENTITLED: (A2018777F)
UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA, PA 19104	23-1352685	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ZHUOHAO HE, PHD, ENTITLED: (A2018802S)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purpose, item (h)

COPY

Part II **Continuation of Grants and Other Assistance to Governments and Organizations in the United States** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
THE TRUSTEES OF COLUMBIA UNIVERSITY - 630 WEST 168TH STREET - NEW YORK, NY 10032	13-5598093	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY OTTAVIO ARANCIO, MD, PHD, ENTITLED: (A2018816S)
WASHINGTON UNIVERSITY 425 S. EUCLID AVENUE ST. LOUIS, MO 63110	43-0653611	501(C)(3)	149,029.	0.			ALZHEIMER'S DISEASE RESEARCH BY JEREMY STRAIN, PHD, ENTITLED: (A2018817F)
CARELIVING, INC. 3100 WEST END AVENUE, SUITE 200 NASHVILLE, TN 37220	82-3809383	N/A	75,000.	0.			ALZHEIMER'S CAREGIVER AWARENESS, EDUCATION, AND SUPPORT.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - 1425 MADISON AVENUE - NEW YORK CITY, NY 10029	13-6171197	501(C)(3)	100,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY EDOARDO MARCORA, PHD, ENTITLED: (A2017458S)
HUMAN COMPUTATION INSTITUTE 12 GENUNG ROAD ITHACA, NY 14850	81-5402321	501(C)(3)	484,910.	0.			ALZHEIMER'S DISEASE RESEARCH BY PIETRO MICHELUCCI, PHD, ENTITLED: (CA2017606)
HUMAN COMPUTATION INSTITUTE 12 GENUNG ROAD ITHACA, NY 14850	81-5402321	501(C)(3)	165,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY PIETRO MICHELUCCI, PHD, ENTITLED: (CA2016629)
MAYO CLINIC, JACKSONVILLE 4500 SAN PABLO ROAD, ROOM 110 JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	60,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ENTITLED: (CA2017563)
UNIVERSITY OF DENVER 2155 E. WESLEY AVENUE DENVER, CO 80208	84-0404231	501(C)(3)	112,210.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANN CHARLOTTE GRANHOLM-BENTLEY, PHD, ENTITLED: (CA2018010)
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER - 5323 HARRY HINES BOULEVARD - DALLAS, TX 75390	75-6002868	501(C)(3)	10,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MARK HENKEMEYER, PHD, ENTITLED: (A2016345S)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purpose, item (h)

COPY

Part II **Continuation of Grants and Other Assistance to Governments and Organizations in the United States** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114	04-1564655	501(C)(3)	556,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JILL GOLDSTEIN, PHD, ENTITLED: (CA2018607)
OREGON HEALTH AND SCIENCE UNIVERSITY - 3181 SW TERWILLIGER BOULEVARD - PORTLAND, OR 97239	93-1176109	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY BENJAMIN SIVYER, PHD, ENTITLED: (G2018011)
CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND, OH 44106	34-1018992	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY JESSICA COOKE BAILEY, PHD, ENTITLED: (G2018042)
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER - 3500 CAMP BOWIE BOULEVARD - FORT WORTH, TX 76107	75-6064033	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY SUCHISMITA ACHARYA, PHD, ENTITLED: (G2018056)
UNIVERSITY OF HOUSTON 4901 CALHOUN ROAD HOUSTON, TX 77204	74-6001399	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY JASON PORTER, PHD, ENTITLED: (G2018061)
SUNY HEALTH SCIENCE CENTER 450 CLARKSON AVENUE BROOKLYN, NY 11203	14-6013200	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY JOHN DANIAS, MD, PHD, ENTITLED: (G2018077)
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER - 5323 HARRY HINES BOULEVARD - DALLAS, TX 75390	04-2103591	501(C)(3)	149,764.	0.			NATIONAL GLAUCOMA RESEARCH BY F. KENT HAMRA, PHD, ENTITLED: (G2018080)
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER - 930 MADISON AVENUE - MEMPHIS, TN 38163	62-1721435	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MONICA JABLONSKI, PHD, ENTITLED: (G2018116)
UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE - 1320 S. DIXIE HWY - CORAL GABELS, FL 33146	59-0624458	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY XIANGRUN HUANG, PHD, ENTITLED: (G2018148)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purpose, item (h)

Part II Continuation of Grants and Other Assistance to Governments and Organizations in the United States (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF WISCONSIN-MADISON 21 N. PARK STREET, SUITE 6401 MADISON, WI 53715	39-6006492	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY ROBERT W. NICKELLS, PHD, ENTITLED: (G2018166)
UNIVERSITY OF ILLINOIS AT CHICAGO 845 W TAYLOR STREET, DEPT. OF CHEM CHICAGO, IL 60607	37-6000511	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY BIJI MATHEW, PHD, ENTITLED: (G2018168)
UNIVERSITY OF AKRON 302 BUCHTEL COMMON AKRON, OH 44325	34-6002924	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY ROUZBEH AMINI, PHD, ENTITLED: (G2018177)
STANFORD UNIVERSITY 3172 PORTER DRIVE PALO ALTO, CA 94304	94-1156365	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY YANG HUMD, PHD, ENTITLED: (G2018183)
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON, TX 77030	74-1159753	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY ROSS POCHE, PHD, ENTITLED: (M2018022)
UNIVERSITY OF CHICAGO 5841 S. MARYLAND AVENUE CHICAGO, IL 60637	36-2177139	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY DIMITRA SKONDRA, MD, PHD, ENTITLED: (M2018042)
THE SCHEPENS EYE RESEARCH INSTITUTE - 20 STANIFORD STREET - BOSTON, MA 02114	42-2129889	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY MAGALI SAINT-GENIEZ, PHD, ENTITLED: (M2018064)
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER - 5323 HARRY HINES BOULEVARD - DALLAS, TX 75390	04-2103591	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY JOHN HULLEMAN, PHD, ENTITLED: (M2018099)
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER - 865 RESEARCH PARKWAY - OKLAHOMA CITY, OK 73104	73-6097060	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY XI-QIN DING, PHD, ENTITLED: (M2018107)

See Schedule O for continuation of Grant Purpose, item (h)

Part II Continuation of Grants and Other Assistance to Governments and Organizations in the United States (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE - 1320 S. DIXIE HWY - MIAMI, FL 33136	59-0624458	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY WILLIAM SCOTT, PHD, ENTITLED: (M2018112)
MASSACHUSETTS EYE AND EAR INFIRMARY - 243 CHARLES STREET - BOSTON, MA 02114	04-2103591	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY ROSARIO FERNANDEZ-GODINO, PHD, ENTITLED: (M2018115)
BOSTON MEDICAL CENTER 650 ALBANY STREET, SUITE 527 BOSTON, MA 02118	04-3314093	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY JI YI, PHD, ENTITLED: (M2018132)
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON, TX 77030	74-1159753	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY YINGBIN FU, PHD, ENTITLED: (M2018142)
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE - LA JOLLA, CA 92093	95-6006144	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY KARL WAHLIN, PHD, ENTITLED: (M2018175)
UNIVERSITY OF KENTUCKY 109 KINKEAD HALL LEXINGTON, KY 40506	61-6033693	501(C)(3)	160,000.	0.			MACULAR DEGENERATION RESEARCH BY MARK KLEINMAN, MD, ENTITLED: (M2018193)
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION - 1201 11TH AVENUE, SOUTH, SUITE 300 - BIRMINGHAM, AL 35205	63-0983733	501(C)(3)	75,000.	0.			2017 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP.
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION - 1201 11TH AVENUE, SOUTH, SUITE 300 - BIRMINGHAM, AL 35205	63-0983733	501(C)(3)	100,000.	0.			2018 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP.
DEAN MCGEE EYE INSTITUTE 608 STANTON YOUNG BOULEVARD OKLAHOMA CITY, OK 73104	73-6109395	501(C)(3)	30,000.	0.			16TH INTERNATIONAL SYMPOSIUM ON RETINAL DEGENERATION 2018 MEETING GRANT.

See Schedule O for continuation of Grant Purpose, item (h)

Part II **Continuation of Grants and Other Assistance to Governments and Organizations in the United States** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
SCHEIE EYE INSTITUTE UNIVERSITY OF PENNSYLVANIA - 51 N 39TH STREET - PHILADELPHIA, PA 19104	23-1352685	501(C)(3)	30,000.	0.			MACULAR DEGENERATION RESEARCH BY BENJAMIN KIM, MD, ENTITLED: (CM2016971)

See Schedule O for continuation of Grant Purpose, item (h)

COPY

Part III **Grants and Other Assistance to Domestic Individuals.** Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

Part IV **Supplemental Information.** Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE IN MOLECULAR BIOLOGY, CELL BIOLOGY, BIOCHEMISTRY, IMAGING AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS

COPY

Part IV Supplemental Information

PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE BOARD OF DIRECTORS SCIENTIFIC AFFAIRS COMMITTEE. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CITATION ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO A STATISTICAL SAMPLE OF WORKS SUPPORTED BY EITHER THE US FEDERAL GOVERNMENT OR THAT OF OTHER FUNDING AGENCIES. BRIGHTFOCUS-SUPPORTED PUBLICATIONS ARE CONSISTENTLY CITED AT NEARLY TWICE THE FREQUENCY OF ANY OTHER COMPARISON GROUP. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES 2.2

Part IV Supplemental Information

ADDITIONAL GRANTS FOR PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT. THESE COME AT VALUES NEARLY 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGHOUT OUR WEBSITE AND WITHIN THE FINAL SCIENTIFIC PROGRESS REPORT, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO WE MAY ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

SCHEDULE J (Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

▶ **Complete if the organization answered "Yes" on Form 990, Part IV, line 23.**
▶ **Attach to Form 990.**
▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Questions Regarding Compensation

		Yes	No
1a	Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.		
	☐ First-class or charter travel		
	☐ Travel for companions		
	☐ Tax indemnification and gross-up payments		
	☐ Discretionary spending account		
	☐ Housing allowance or residence for personal use		
	☐ Payments for business use of personal residence		
	☐ Health or social club dues or initiation fees		
	☐ Personal services (such as, maid, chauffeur, chef)		
b	If any of the boxes on line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain 1b		
2	Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, and officers, including the CEO/Executive Director, regarding the items checked on line 1a? 2		
3	Indicate which, if any, of the following the filing organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.		
	☒ Compensation committee		
	☒ Independent compensation consultant		
	☒ Form 990 of other organizations		
	☐ Written employment contract		
	☒ Compensation survey or study		
	☒ Approval by the board or compensation committee		
4	During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:		
a	Receive a severance payment or change-of-control payment? 4a		X
b	Participate in, or receive payment from, a supplemental nonqualified retirement plan? 4b		X
c	Participate in, or receive payment from, an equity-based compensation arrangement? 4c		X
	If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.		
	Only section 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.		
5	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:		
a	The organization? 5a		X
b	Any related organization? 5b		X
	If "Yes" on line 5a or 5b, describe in Part III.		
6	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:		
a	The organization? 6a		X
b	Any related organization? 6b		X
	If "Yes" on line 6a or 6b, describe in Part III.		
7	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described on lines 5 and 6? If "Yes," describe in Part III 7	X	
8	Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III 8		X
9	If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? 9		

Part II **Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees.** Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

Note: The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
(1) STACY PAGOS HALLER	(i)	348,215.	45,000.	2,571.	40,500.	37,321.	473,607.	0.
PRESIDENT/CEO	(ii)	0.	0.	0.	0.	0.	0.	0.
(2) NANCY LYNN	(i)	229,280.	0.	1,032.	4,994.	23,965.	259,271.	0.
SR. VP STRATEGIC PARTNERSHIPS	(ii)	0.	0.	0.	0.	0.	0.	0.
(3) R. BRIAN ELDERTON	(i)	221,431.	0.	1,584.	15,203.	23,076.	261,294.	0.
SR. VP, DEVELOPMENT	(ii)	0.	0.	0.	0.	0.	0.	0.
(4) DAVID F. MARKS, CPA, CMA	(i)	151,588.	0.	1,032.	24,581.	37,273.	214,474.	0.
VP, FINANCE & ADMINISTRATION	(ii)	0.	0.	0.	0.	0.	0.	0.
(5) DIANE BOVENKAMP, PHD	(i)	152,025.	0.	360.	22,804.	3,134.	178,323.	0.
VP, SCIENTIFIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
(6) MICHAEL BUCKLEY	(i)	143,920.	0.	360.	22,611.	22,723.	189,614.	0.
VP, PUBLIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							

COPY

Part III Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

PART I, LINE 7:

AS THE PRESIDENT/CEO'S BONUS WAS NOT A FIXED PAYMENT SPECIFIED IN HER EMPLOYMENT CONTRACT, THIS ITEM HAS BEEN ANSWERED 'YES' IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE INSTRUCTIONS. HOWEVER, IT SHOULD BE NOTED THAT HER BONUS WAS A NON-FIXED PAYMENT BASED ON BRIGHTFOCUS' INTERNAL PROCEDURES.

THE BOARD OF DIRECTORS CONSIDERS THE AWARD OF A DISCRETIONARY BONUS EACH YEAR. THE DETERMINATION OF THE BONUS COMPENSATION IS CAPPED AS SPECIFIED IN HER EMPLOYMENT CONTRACT, AND IF NOT WARRANTED WILL NOT BE AWARDED AT ALL. THE DETERMINATION IS MADE BY THE FULL BOARD UPON RECOMMENDATION OF ITS EXECUTIVE COMMITTEE THAT IS RESPONSIBLE FOR THE REVIEW OF PRESIDENT/CEO COMPENSATION. THE COMMITTEE CONSIDERS A SET OF GOALS FOR THE PRESIDENT/CEO'S PERFORMANCE DEVELOPED AT THE BEGINNING OF THE YEAR IN CONSULTATION WITH THE PRESIDENT/CEO. EACH GOAL IS EVALUATED AT THE END OF THE FISCAL YEAR TO DETERMINE WHETHER THE GOAL HAS BEEN MET OR EXCEEDED.

THE BONUS IS AWARDED BASED ON A DETAILED REVIEW BY THE BOARD OF DIRECTORS OF WHETHER EACH GOAL HAS BEEN MET OR EXCEEDED.

SCHEDULE M (Form 990)

Department of the Treasury
Internal Revenue Service

Noncash Contributions

▶ Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017

Open To Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Types of Property

		(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1	Art - Works of art				
2	Art - Historical treasures				
3	Art - Fractional interests				
4	Books and publications				
5	Clothing and household goods				
6	Cars and other vehicles				
7	Boats and planes				
8	Intellectual property				
9	Securities - Publicly traded	X	19	180,229.	FMV
10	Securities - Closely held stock				
11	Securities - Partnership, LLC, or trust interests				
12	Securities - Miscellaneous				
13	Qualified conservation contribution - Historic structures				
14	Qualified conservation contribution - Other				
15	Real estate - Residential				
16	Real estate - Commercial				
17	Real estate - Other				
18	Collectibles				
19	Food inventory				
20	Drugs and medical supplies				
21	Taxidermy				
22	Historical artifacts				
23	Scientific specimens				
24	Archeological artifacts				
25	Other ▶ ( )				
26	Other ▶ ( )				
27	Other ▶ ( )				
28	Other ▶ ( )				

29 Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part IV, Donee Acknowledgement 29

		Yes	No
30a	During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period?		X
b	If "Yes," describe the arrangement in Part II.		
31	Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?	X	
32a	Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions?		X
b	If "Yes," describe in Part II.		
33	If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II.		

Part II **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):

BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN (B).

SCHEDULE O (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on Form 990 or 990-EZ or to provide any additional information.
▶ Attach to Form 990 or 990-EZ.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:

BRIGHTFOCUS FOUNDATION DRIVES INNOVATIVE RESEARCH WORLDWIDE AND PROMOTES AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA. OUR VISION IS LIVING FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, 1 IN 16 PEOPLE OVER THE AGE OF 40 IN THE U.S. HAS ONE OF THESE DISEASES.

BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING BETTER UNDERSTANDING, TREATMENTS, OR, ULTIMATELY, A CURE FOR THESE DISEASES. SINCE 1973, BRIGHTFOCUS HAS AWARDED MORE THAN $190 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS AROUND THE WORLD. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO THE UNDERSTANDING OF THESE DISEASES AND TO THE AWARDING OF TWO NOBEL PRIZES. BRIGHTFOCUS-SUPPORTED FINDINGS ARE CONSISTENTLY CITED BY OTHER SCIENTISTS AT TWICE THE FREQUENCY AS OTHER RESEARCH FINDINGS.

OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH. THE BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM OTHER SOURCES THAT ARE 10 TIMES LARGER THAN THE ORIGINAL BRIGHTFOCUS AWARD. THIS ONE THOUSAND PERCENT RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS. INDISPUTABLY, THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS MORE THAN PROMISING: IT IS MAKING A REAL CONTRIBUTION TO REVOLUTIONARY SCIENCE IN THE FIGHT TO SAVE MIND AND SIGHT.

ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES TO SOME OF SOCIETY'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE EDUCATIONAL MATERIALS AND SUPPORT TO HUNDREDS OF THOUSANDS OF PATIENTS AND FAMILIES AFFECTED BY THESE DISEASES NATIONWIDE. WE BASE THESE EDUCATIONAL MATERIALS OFF OF THE LATEST RESEARCH FINDINGS.

BRIGHTFOCUS INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS.

BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSA) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. BOTH MAKE A PLAN TODAY: GET YOUR EYES CHECKED AND NOW IS THE MOMENT TO STOP ALZHEIMER'S DISEASE POWERFULLY SEEK TO RAISE AWARENESS AND EARLY DETECTION, AND SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES AND SUPERMARKETS. IN FISCAL YEAR 2018, THESE PSA MESSAGES GENERATED $13,658,057 IN DONATED MEDIA SERVICES AND GARNERED 1.3 BILLION IMPRESSIONS.

STARTING IN FEBRUARY 2014, WE LAUNCHED BRIGHTFOCUS CHATS, A FREE,

INTERACTIVE MONTHLY TELEPHONE FORUM THAT BRINGS TOGETHER PATIENTS AND CAREGIVERS TO LEARN FROM, AND ASK QUESTIONS OF, LEADING RESEARCHERS AND SPECIALISTS ON VISION DISEASES. THE CHATS ARE ARCHIVED ON OUR WEB SITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN A NUMBER OF ACCESSIBLE FORMATS.

WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY UNVEIL NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES. WE HAVE EXPANDED OUR WRITTEN CONTENT OF KEY RESEARCH FINDINGS, PROMOTING AND SHARING THIS INFORMATION THROUGH OUR WEB SITE AND SOCIAL MEDIA PLATFORMS. CAPITALIZING ON EMERGING USE OF DATA VISUALIZATION, OUR BRIGHTFOCUS INFOGRAPHICS EASILY AND VISUALLY COMMUNICATE INFORMATION ON ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA.

MORE SPECIFICALLY, EACH OF THESE PROGRAM AREAS MAIL AWARENESS-RAISING MATERIALS TO HUNDREDS OF THOUSANDS OF HOUSEHOLDS, WITH MESSAGES FOCUSING ON:

- RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK.
- LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE.
- RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE.

BRIGHTFOCUS REGULARLY INTERACTS WITH MEMBERS OF THE MEDIA, AS WELL AS ELECTED OFFICIALS AND FEDERAL AGENCY STAFF. THROUGH OUR OWN OUTREACH

EFFORTS, AS WELL AS ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH, AND SEARCHING FOR CURES FOR, THESE TERRIBLE DISEASES.

BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS.

FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS:
NOTABLE PROJECTS INCLUDE: A FOCUS ON AN INTERNATIONAL BIOSAMPLE AND BRAIN BANK FOR BIOMARKER DISCOVERY FOR HIGH RISK ALZHEIMER'S GROUPS; DETERMINING RISK ALGORITHMS IN MIDDLE AGE FOR ALZHEIMER'S IN MEN AND WOMEN; SCIENTIFIC EXCHANGES; AND BETTER USE OF MODERN TECHNOLOGIES, INCLUDING MOBILE TECHNOLOGIES AND BIG DATA, TO INCREASE THE SPEED OF CLINICAL TRIALS AND RESEARCH PROGRESS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I.

BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO EVENTUAL NOBEL PRIZE WINNERS: DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL TO OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE.

BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL

"MOLECULAR NEURODEGENERATION" AS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. AS AN "OPEN ACCESS" JOURNAL, THERE IS NO FEE FOR READERS, AND ALL CONTENT IS FREE OF CHARGE AND EASY TO ACCESS. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST IMPACT OPEN ACCESS JOURNAL IN THE NEUROSCIENCES.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG. ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. MORE THAN 5 MILLION AMERICANS AGED 65 AND OLDER ARE THOUGHT TO HAVE ALZHEIMER'S DISEASE TODAY, AND THAT NUMBER IS EXPECTED TO TRIPLE BY MIDCENTURY.

FORM 990, PART III, LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS:
IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG. AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE

60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ.

FORM 990, PART III, LINE 4C, PROGRAM SERVICE ACCOMPLISHMENTS:

DURING THE FISCAL YEAR ENDING MARCH 31, 2018, NGR AWARDED $1,899,310 FOR 13 NEW PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG. GLAUCOMA IS A GROUP OF DISEASES THAT DAMAGE THE EYE'S OPTIC NERVE AND CAN RESULT IN VISION LOSS AND PERMANENT BLINDNESS. MORE THAN 3 MILLION AMERICANS AGE 40 AND OLDER HAVE GLAUCOMA. MORE THAN 60 MILLION PEOPLE IN THE WORLD HAVE THE DISEASE, AND THAT NUMBER IS EXPECTED TO INCREASE BY AS MUCH AS 20 MILLION BY 2020. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS, BUT IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE.

FORM 990, PART VI, SECTION B, LINE 11B:

A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.

FORM 990, PART VI, SECTION B, LINE 12C:

BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNAUALLY.

EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.

FORM 990, PART VI, SECTION B, LINE 15:

BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR.

BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE IN LIGHT OF THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED ANNUALLY BY THE BOARD OF DIRECTORS THROUGH THE USE OF AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, (DEVELOPED WITH ADVICE FROM BOARD SOURCE) THAT INCLUDES A SELF ASSESSMENT AND A BOARD OF DIRECTORS ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN LIKE CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS SHALL CONSIDER TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING.

THE BOARD SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE IN LIGHT OF THE EVALUATION AND COMPARABILITY DATA.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

THE PRESIDENT/CEO IS CHARGED WITH THE SETTING OF SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990:

AK,AL,AR,AZ,CA,CT,FL,GA,HI,IL,KS,KY,ME,MD,MA,MI,MN,MO,MS,NC,ND,NH,NJ,NM,NY OH,OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

FORM 990, PART VI, SECTION C, LINE 19:

BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON OUR WEBSITE.

FORM 990, PART XI, LINE 9, CHANGES IN NET ASSETS:

RECOVERIES OF PRIOR YEAR GRANTS	361,983.
CHANGE IN PRESENT VALUE OF GRANTS	122,750.
TOTAL TO FORM 990, PART XI, LINE 9	484,733.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

SCHEDULE F, PART II, LINE 1, COLUMN D:

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY YIM LUI CAROL CHEUNG, PHD, ENTITLED: (A2018093S) RECOGNITION OF RETINAL FINGERPRINT FOR ALZHEIMER'S DISEASE USING DEEP LEARNING APPROACH. INVESTIGATOR'S SUMMARY: EARLY DETECTION OF ALZHEIMER'S DISEASE (AD) ALLOWS EARLY INTERVENTION TO ITS UPSTREAM PATHOLOGY, WHICH IS MORE LIKELY TO PREVENT OR DELAY COGNITIVE DECLINE AS SUGGESTED BY CURRENT EVIDENCE, YET CURRENT DIAGNOSTIC METHOD FOR EARLY AD ARE NOT APPLICABLE TO POPULATION-BASED SCREENING. BEING AN EXTENSION OF THE BRAIN, OUR EYE IS ALSO AFFECTED BY AD AND EYES FROM SUBJECTS WITH AD EXHIBIT A STRUCTURAL PATTERN THAT MAY BE USED AS A "RETINAL FINGERPRINT" FOR EARLY DETECTION. IN THIS STUDY, AN ARTIFICIAL INTELLIGENCE (AI) WILL "LEARN" THESE RETINAL PATTERNS WITH DEEP LEARNING METHODS AND, AFTER THAT, WILL BE ABLE TO IDENTIFY EYES FROM INDIVIDUALS WITH AD. THIS TECHNIQUE ONLY REQUIRES A ROUTINE EYE-CHECK, AND REPRESENTS AN INEXPENSIVE, NON-INVASIVE, EFFICIENT AND ACCESSIBLE METHOD FOR IDENTIFYING WHO ARE MORE LIKELY TO HAVE AD. GRANT AWARDED: $300,000, THE CHINESE UNIVERSITY OF HONG KONG, CHINA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018093S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SAIMA HILAL, PHD, ENTITLED: (A2018165F) THE CLINICAL RELEVANCE OF CORTICAL CEREBRAL MICROINFARCTS IN DEGENERATIVE BRAIN PATHOLOGY SUCH AS ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DAMAGE TO THE SMALL VESSELS IN THE BRAIN ARE ONE OF THE MAJOR CAUSE OF ALZHEIMER'S DISEASE (AD). ADEQUATE TREATMENT IS CURRENTLY NOT AVAILABLE BECAUSE THE EXACT PROCESS BEHIND THIS DISEASE IS STILL UNKNOWN. WITH THIS PROPOSAL, WE

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

AIM TO FIND THE CAUSE FOR AD BY FINDING SMALL STROKES IN THE BRAIN. THIS WILL HELP US UNDERSTAND WHY AD IS SO COMMON IN PEOPLE WITH SMALL STROKES AND WILL HELP CREATE MEANS TO CURE AND PREVENT THIS DISEASE. GRANT AWARDED: $150,000, ERASMUS MEDICAL CENTER, ROTTERDAM, NETHERLANDS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018165F

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY STEPHANIE RAINEY-SMITH, PHD, ENTITLED: (A2018402F) IMPROVING SLEEP TO PREVENT ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS A TERRIBLE ILLNESS WHICH DAMAGES THE BRAIN OF MANY OLDER PEOPLE, CAUSING THEM TO STOP THINKING CLEARLY, TO STOP REMEMBERING IMPORTANT INFORMATION ABOUT THEMSELVES, THEIR FAMILY AND THEIR LIFE, AND TO START BEHAVING DIFFERENTLY; THESE PROBLEMS GET SO BAD THAT DAILY TASKS SUCH AS DRIVING, READING OR FINDING THE RIGHT WORDS WHEN SPEAKING TO SOMEONE BECOME VERY DIFFICULT OR IMPOSSIBLE. WE KNOW THAT A PARTICULAR PROTEIN BUILDS UP IN THE BRAIN OF A PERSON WITH AD AND THAT THE BRAIN BECOMES SMALLER, BUT WE DON'T KNOW HOW TO SLOW OR STOP THE DISEASE. SOME SCIENTISTS BELIEVE THAT SLEEP IS IMPORTANT, BUT MORE WORK IS NEEDED TO UNDERSTAND WHETHER 'HOW LONG' AND 'HOW WELL' SOMEONE USUALLY SLEEPS CHANGES HOW LIKELY THEY ARE TO GET AD, OR ALTERS THE SPEED AT WHICH THE CHANGES IN THE BRAIN HAPPEN. THIS STUDY WILL EXPLORE THE RELATIONSHIP BETWEEN SLEEP, MEMORY AND THINKING, AND CHANGES IN THE BRAIN, BY INVESTIGATING WHETHER IMPROVED SLEEP (BETTER AND LONGER) CAUSES BETTER MEMORY AND THINKING, SLOWER PROTEIN BUILD UP IN THE BRAIN AND SLOWS THE SHRINKING OF THE BRAIN, WITH THE RESULTS OF THIS PROJECT HOPEFULLY HELPING TO FIND A WAY TO SLOW OR STOP THIS HORRIBLE DISEASE. GRANT AWARDED: $149,998, EDITH COWAN UNIVERSITY,

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

JOONDALUP, WESTERN AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018402F

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BRETT COLLINS, PHD, ENTITLED: (A2018627S) STABILIZING THE RETROMER PROTEIN COMPLEX WITH MOLECULAR CHAPERONES FOR ALZHEIMER'S AND PARKINSON'S DISEASES. INVESTIGATOR'S SUMMARY: WITH OUR AGING POPULATION COMES AN EVER-INCREASING INCIDENCE OF ALZHEIMER'S DISEASE (AD), AND OTHER AGE-RELATED DEMENTIAS. BY THE YEAR 2050, THERE IS FORECAST TO BE MORE THAN 13 MILLION PEOPLE LIVING WITH AD IN THE USA AND NEW TREATMENTS ARE DESPERATELY NEEDED TO PREVENT THIS IMPENDING EPIDEMIC. THERE ARE CURRENTLY NO EFFECTIVE THERAPIES FOR AD, WITH CURRENT CLINICAL TRIALS ALL ATTEMPTING TO DIRECTLY TARGET AMYLOID (A-BETA) PEPTIDES THOUGHT TO BE THE DRIVER OF NEURONAL DEGENERATION. IN THE LONG TERM, SCIENTISTS BELIEVE THAT WE MAY HAVE TO USE COCKTAILS OF DRUGS TO EFFECTIVELY SLOW THE DISEASE, MUCH AS WE NOW DO FOR DISEASES SUCH AS HIV/AIDS. A NEW CONCEPT IN AD RESEARCH IS THAT CELLULAR PROCESSES REGULATING PROTEIN TURNOVER COULD BE MANIPULATED TO PREVENT THE BUILD-UP OF THE TOXIC A-BETA PEPTIDES THAT CAUSE NEUROLOGICAL FAILURE. IN THIS WORK WE WILL BE DEVELOPING NOVEL SMALL MOLECULES AND PEPTIDES THAT WE HOPE WILL ENHANCE THIS PROTEIN TURNOVER IN NEURONS, AND PROVIDE A STARTING POINT FOR DESIGNING NEW AD DRUGS. GRANT AWARDED: $191,034, THE UNIVERSITY OF QUEENSLAND, BRISBANE, QUEENSLAND, AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018627S

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SANJEEV KUMAR, MD, FRCPC, ENTITLED: (A2018667S) IDENTIFYING

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

AND TARGETING CORTICAL INHIBITION DEFICITS IN AGITATION/AGGRESSION DUE TO ALZHEIMER'S DEMENTIA. INVESTIGATOR'S SUMMARY: AGITATION AND AGGRESSION AFFECT MAJORITY OF PATIENTS WITH ALZHEIMER'S DEMENTIA (AD). MEDICATIONS USED TO TREAT THESE SYMPTOMS ARE ASSOCIATED WITH MANY SIDE EFFECTS. WE ARE PROPOSING TO USE MAGNETIC BRAIN STIMULATION TO UNDERSTAND THE MECHANISMS OF AGITATION IN AD AND USE A NON-INVASIVE BRAIN STIMULATION TECHNIQUE CALLED TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) TO TREAT AGITATION. IF SUCCESSFUL THIS STUDY WILL LEAD TO DEVELOPMENT OF A SAFE AND EFFECTIVE TREATMENT FOR AGITATION IN AD. GRANT AWARDED: $300,000, CENTRE FOR ADDICTION AND MENTAL HEALTH, TORONTO, CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018667S

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BENJAMIN HOGAN, PHD, ENTITLED: (A2018807S) CHARACTERIZATION OF A NEWLY DESCRIBED SCAVENGER CELL TYPE IN THE MENINGEAL VASCULATURE. INVESTIGATOR'S SUMMARY: NORMAL FUNCTION OF THE BRAIN VASCULATURE AND THE CLEARANCE OF HARMFUL WASTES FROM THE BRAIN ARE CENTRAL IN THE PROGRESSION OF ALZHEIMER'S DISEASE. THIS PROJECT FOCUSED ON UNDERSTANDING A CELL TYPE THAT SURROUNDS BLOOD VESSELS IN THE BRAIN AND ACTIVELY CLEARS POTENTIALLY HARMFUL DEBRIS AND WASTE. WE WILL DETERMINE THE ROLE PLAYED BY THIS CELL TYPE IN CLEARANCE OF WASTES IN AGING BRAINS AND THE POTENTIAL ROLE OF THIS CELL TYPE IN NEURODEGENERATION. WE AIM TO DEVELOP A NEW UNDERSTANDING OF HOW THE BRAIN IS CLEANED WITH A HOPE THAT MANIPULATING THESE PROCESSES IN THE FUTURE MIGHT PROVIDE A NEW STRATEGY TO FIGHT DISEASE PROGRESSION. GRANT AWARDED: $295,439, THE UNIVERSITY OF QUEENSLAND, BRISBANE, QUEENSLAND, AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

WWW.BRIGHTFOCUS.ORG/GRANT/A2018807S

SCHEDULE F, PART II, LINE 1, COLUMN D:

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY YUAN LEI, PHD, ENTITLED: (G2018112) THE ROLE OF MICRO RNA21 IN REGULATING AQUEOUS HUMOR OUTFLOW. INVESTIGATOR'S SUMMARY: THE MOST EFFECTIVE THERAPY FOR GLAUCOMA IS REDUCING EYE PRESSURE, BUT IT IS NOT UNDERSTOOD HOW THE PRESSURE IN THE EYE IS REGULATED. MICRO RNAS ARE VERY SMALL GENETIC SEQUENCES THAT CAN REGULATE THE EXPRESSION OF MANY GENES. IN FACT, A SINGLE MICRO RNA IS SO POWERFUL THAT IT CAN MODULATE SEVERAL GENES. THE AIM OF THIS PROJECT IS TO UNDERSTAND THE ROLE OF A VERY IMPORTANT MICRO RNA NAMELY MICRO RNA21 IN REGULATING IOP. THIS MAY BE A VERY EFFECTIVE NEW WAY TO TREAT ELEVATED EYE PRESSURE IN AN EYE DISEASE CALLED GLAUCOMA. GRANT AWARDED: $99,546, EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY, SHANGHAI, CHINA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018112

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION DISEASE RESEARCH BY FLORIAN SENNLAUB, MD, PHD, ENTITLED: (M2018096) INFLUENCE OF CHRONIC INTERMITTENT HYPOXIA ON NEUROINFLAMMATION IN AGE RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: IT HAS RECENTLY BEEN SHOWN THAT PATIENTS WITH SLEEP APNEA SYNDROME (SAS) SUFFER MORE FREQUENTLY FROM AGE-RELATED MACULAR DEGENERATION, BUT THE REASON FOR THE ASSOCIATION OF BOTH DISEASES REMAINS OBSCURE. OUR PRELIMINARY DATA SUGGEST THAT THE EPISODES OF HYPOXIA THAT CHARACTERIZE SLEEP APNEA, ACTIVATE CIRCULATING IMMUNE CELLS AND LEAD TO LONGER AND STRONGER DETRIMENTAL INFLAMMATION IN THE EYE IN AMD MODELS. OUR PROPOSAL TO STUDY IMMUNE CELL ACTIVATION AND DETRIMENTAL INFLAMMATION BY HYPOXIA

MIGHT HELP EXPLAIN THE ASSOCIATION OF SLEEP APNEA WITH AMD, BUT ALSO OF DISEASES SUCH AS ALZHEIMER'S DISEASE THAT ARE ASSOCIATED WITH SAS AND HARMFUL INFLAMMATION. INCREASED AWARENESS OF THIS MECHANISM WILL HELP TO DIAGNOSE AND TREAT SAS IN AFFECTED AMD PATIENTS, REDUCING THEIR NEED FOR INTRA-VITREAL INJECTIONS AND SLOWING THE DEGENERATION IN THE FUTURE. GRANT AWARDED: $160,000, INSTITUTE DE LA VISION, PARIS, FRANCE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018096

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY CHI LUU, PHD, ENTITLED: (M2018144) RECONSTITUTED HIGH DENSITY LIPOPROTEIN (RHDL) FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD). INVESTIGATOR'S SUMMARY: IN THIS PROJECT, WE WILL EXAMINE THE ROLE OF CHOLESTEROL ON THE DEVELOPMENT AND PROGRESSION OF AMD, AN EYE CONDITION THAT CAUSES THE LOSS OF CENTRAL VISION. WE WILL ALSO INVESTIGATE WHETHER AMD CAN BE TREATED WITH "GOOD CHOLESTEROL." THE FINDINGS FROM THIS PROJECT WILL PAVE THE WAY FOR THE DEVELOPMENT OF NEW THERAPIES FOR THE MANAGEMENT OF THE EARLIEST CHANGES IN AMD TO PREVENT VISION LOSS. THERE ARE NO TREATMENT OPTIONS CURRENTLY AVAILABLE FOR THE EARLY STAGES ON AMD TO PREVENT ITS PROGRESSION TO VISION LOSS. GRANT AWARDED: $160,000, CENTRE FOR EYE RESEARCH AUSTRALIA, EAST MELBOURNE, AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018144

SCHEDULE I, PART II, LINE 1, COLUMN (H):

NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CONGCONG HE, PHD, ENTITLED: (A2018100S) MECHANISMS OF AUTOPHAGIC REGULATION OF A-BETA

METABOLISM AGAINST ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: AUTOPHAGY, THE PATHWAY A BRAIN CELL USES TO DISPOSE OF DAMAGED STRUCTURES INSIDE THE CELL, IS IMPAIRED IN ALZHEIMER'S DISEASE (AD). BRAIN CELLS PRODUCE AMYLOID, A TOXIC PEPTIDE THAT CAUSES AD. OUR RESEARCH WILL SHOW HOW ACTIVATED AUTOPHAGY CAN RECOGNIZE AND CLEAR AMYLOIDS IN DIFFERENT TYPES OF BRAIN CELLS, AND HOW TO INCREASE THE ACTIVITY OF THIS PATHWAY TO ACCELERATE THE DISPOSAL OF AMYLOIDS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018100S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHAO WANG, PHD, ENTITLED: (A2018128F) LDLR-TARGETED THERAPY FOR APOE-RELATED TAUOPATHY. INVESTIGATOR'S SUMMARY: TAU PROTEIN AGGREGATION IN NEURONS IS ONE OF THE HALLMARKS FOR ALZHEIMER'S DISEASE (AD). THE APOE GENE IS A STRONG RISK FACTOR FOR AD AND DIRECTLY AFFECTS TAU PATHOLOGY AND TAU-MEDIATED NEURODEGENERATION. THEREFORE, WE WILL ASK IF DECREASING APOE LEVELS IN THE BRAIN CAN ALTER TAU AGGREGATION AND TAU-INDUCED NEURODEGENERATION, AND WE WILL ALSO TRY TO DETERMINE HOW APOE EXERTS ITS EFFECTS ON TAU. UNDERSTANDING THESE QUESTIONS WILL POTENTIALLY HELP US TO DEVELOP NOVEL TREATMENTS FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018128F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF FLORIDA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CARA CROFT, PHD, ENTITLED: (A2018149F) UNDERSTANDING AND TARGETING TAU-INDUCED NEURODEGENERATION. INVESTIGATOR'S SUMMARY: TAU IS ONE OF THE TWO MAJOR PROTEINS THAT CHANGES AND THEN BUILDS UP IN THE BRAIN IN ALZHEIMER'S DISEASE AND HOW

IT IS LINKED TO BRAIN CELL DEATH IS STILL UNCLEAR. USING A MOUSE ALZHEIMER'S-IN-A-DISH MODEL SIMILAR TO THE AD DIAGNOSED IN PATIENTS, THE RESEARCHERS WILL TRY TO UNDERSTAND WHY SOME PEOPLE HAVE BUILDUP OF TAU AND OTHERS DON'T. THEN THEY WILL TREAT THE TISSUES TO TRY AND PREVENT THE TAU BUILDUP. THIS WILL HELP US UNDERSTAND IF WE ARE ABLE TO TREAT HUMANS WITH AD IN A SIMILAR WAY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018149F

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TIMOTHY MILLER, MD, PHD, ENTITLED: (A2018169S) ANTISENSE-MEDIATED TREM2 KNOCKDOWN TO LESSEN AMYLOID AND TAU PATHOLOGY. INVESTIGATOR'S SUMMARY: UNDERSTANDING THE GENETIC RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE (AD) IS IMPORTANT FOR IDENTIFYING AND DIRECTING SUCCESSFUL TREATMENT STRATEGIES. OF THESE RISKS, A GENE INVOLVED IN INFLAMMATORY RESPONSES (TREM2) INCREASES RISK FOR DEVELOPING AD AND APPEARS TO MEDIATE THE ACCUMULATION OF TOXIC PROTEIN AMYLOID BETA IN THE BRAINS OF MICE WITH AD. WE PROPOSE A STRATEGY THAT CAN REDUCE TREM2 EXPRESSION IN THE CONTEXT OF AD AND WILL INVESTIGATE PATHOLOGY AND INFLAMMATION IN RESPONSE TO TREM2 LOSS. OUR RESULTS WILL IDENTIFY THE ROLE OF TREM2 IN AD AND HELP DIRECT FUTURE TREM2-TARGETED THERAPIES FOR AD PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018169S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HOLLY CUKIER, PHD, ENTITLED: (A2018197S) ELUCIDATING THE CELL-SPECIFIC ROLES OF ABCA7. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) OCCURS

MORE FREQUENTLY IN DIVERSE POPULATIONS (I.E.: AFRICAN AMERICANS AND HISPANICS) THAN WHITE POPULATIONS. THIS PROPOSAL SEEKS TO INVESTIGATE THE ROLE OF A GENE SHOWN TO BE A RISK FACTOR FOR AD, ABCA7, AND THE CONSEQUENCE OF A MUTATION THAT WAS FIRST IDENTIFIED IN AFRICAN AMERICANS. STEM CELL LINES HAVE BEEN GENERATED FROM AFRICAN AMERICANS WITH THIS DELETION AND BOTH NEURONS AND CELLS INVOLVED IN IMMUNITY, MICROGLIA, WILL BE CREATED. USING THESE TWO CELL TYPES, WE WILL INVESTIGATE HOW THIS DELETION MAY AFFECT THE NORMAL WAY NEURONS AND MICROGLIA DEVELOP, AND HOW THEY MAY LEAD TO AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018197S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JASON HASSENSTAB, PHD, ENTITLED: (A2018202S) RAPID, REMOTE, AND RELIABLE: SMARTPHONE-BASED BURST COGNITIVE ASSESSMENTS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WE RELY ON COMPLEX MEMORY AND THINKING SKILLS TO FUNCTION IN EVERYDAY LIFE, HOWEVER, THESE SKILLS FLUCTUATE CONSTANTLY DUE TO FATIGUE, STRESS, AND ANXIETY--AND THESE FLUCTUATIONS INCREASE AS WE AGE. DESPITE THIS, WHEN WE STUDY PEOPLE AT RISK FOR ALZHEIMER'S DISEASE (AD), WE TEST MEMORY AND THINKING IN "ONE-SHOT" IN A UNFAMILIAR PLACE (USUALLY A CLINIC OR HOSPITAL EXAM ROOM). SOME PERFORM REALLY WELL ON A "GOOD" DAY AND OTHERS MAY PERFORM MORE POORLY ON A "BAD" DAY. THESE FLUCTUATIONS MAKE IT EXTRAORDINARILY DIFFICULT TO MEASURE TRUE ABILITIES. IN THIS STUDY, WE PROPOSE TO USE SMARTPHONES TO TEST MEMORY AND THINKING IN SHORT "BURSTS", REQUIRING LESS THAN 3 MINUTES EACH TO COMPLETE. PARTICIPANTS CAN TAKE TESTS WHEREVER IT IS SAFE TO USE A SMARTPHONE AND THEY TAKE THE TESTS MULTIPLE TIMES PER DAY, WHICH PROVIDES MUCH MORE ACCURATE AND RELIABLE TESTS TO BETTER UNDERSTAND HOW

MEMORY AND THINKING CHANGE IN VERY EARLY AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018202S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GOONHO PARK, PHD, ENTITLED: (A2018212F) DENDRITIC SPINE LOSS IN ALZHEIMER DISEASE: ROLE OF CASPASE CLEAVAGE OF THE AMYLOID PRECURSOR PROTEIN (APP). INVESTIGATOR'S SUMMARY: NEURONS COMMUNICATE TO ONE ANOTHER BY FORMING SYNAPSES IN THE BRAIN. FOR REASONS THAT ARE NOT COMPLETELY CLEAR, THESE SYNAPTIC CONNECTIONS ARE SUSCEPTIBLE TO DAMAGE AND ARE LOST IN THE EARLY STAGES OF AD. INJURY AND LOSS OF SYNAPSES IN BRAIN ARE BELIEVED TO BE A MAJOR REASON FOR COGNITIVE IMPAIRMENT SEEN IN INDIVIDUALS WITH ALZHEIMER'S DISEASE (AD). AMYLOID BETA-PEPTIDE, WHICH IS GENERATED FROM APP, IS HYPOTHESIZED TO BE ONE OF THE MAJOR REASONS FOR SYNAPTIC DAMAGE. IN ADDITION, HOWEVER, APP ALSO GENERATES ANOTHER FRAGMENT WHICH WE HYPOTHESIZE COULD PLAY AN ADDITIONAL ROLE IN SYNAPTIC INJURY. IN THIS PROJECT, WE WILL TEST WHETHER THE BLOCKING OF THE GENERATION OF THIS FRAGMENT FROM APP CAN PROTECT SYNAPSES FROM INJURY AND DAMAGE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018212F

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSEPH CASTELLANO, PHD, ENTITLED: (A2018213S) PLASMA PROTEIN-MEDIATED EFFECTS OF APOE4 EXPRESSION ON BRAIN IN AD. INVESTIGATOR'S SUMMARY: POSSESSION OF THE APOE-4 GENE CONFERS A STRONG RISK FOR EARLIER ONSET FOR ALZHEIMER'S DISEASE (AD), A DEVASTATING BRAIN DISORDER THAT DAMAGES SYNAPSES AND ULTIMATELY NEURONS RESPONSIBLE FOR MEMORY AND LEARNING AS

WELL AS EXECUTIVE FUNCTION. WHILE IT IS CLEAR THAT AD CREATES WIDESPREAD DAMAGE WITHIN THE BRAIN ITSELF, IT IS UNCLEAR WHETHER THE UPSTREAM CAUSE OF THE DISEASE MAY LIE IN CHANGES THAT OCCUR IN THE BLOOD, ULTIMATELY INFLUENCING BRAIN HEALTH, A HYPOTHESIS FOR WHICH THERE IS SUPPORT IN THE CONTEXT OF NORMAL AGING. THIS PROPOSAL WILL DIRECTLY INVESTIGATE HOW MANIPULATING PROTEINS IN THE BLOOD INFLUENCES THE ABILITY OF THE RISKY APOE-4 GENE TO INFLUENCE DEVELOPMENT OF AD AND THE EXTENT TO WHICH IT CAN BE RESCUED WITH MORE NEUTRAL FORMS OF THE GENE, POSSIBLY PROVIDING FRESH INSIGHTS INTO NEW TREATMENT AVENUES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018213S

SCHEDULE I, PART II, LINE 1, COLUMN (H):
NAME OF ORGANIZATION OR GOVERNMENT: SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY YINGJUN ZHAO, PHD, ENTITLED: (A2018214F) TARGETING SYNAPTIC AND MEMORY DEFICITS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE MOST PREVALENT NEURODEGENERATIVE DISORDER WORLD-WIDE, AND HAS DEVASTATING EFFECTS ON MEMORY AND BRAIN FUNCTION IN AFFLICTED PATIENTS. ALTHOUGH THE EXACT CAUSES THAT ACCELERATE MEMORY LOSS DURING AGING IS NOT KNOWN, IT IS LIKELY THAT A TOXIC PROTEIN A-BETA PLAYS A VITAL ROLE IN DISRUPTING COMMUNICATION JUNCTIONS IN THE BRAIN AS AD PROGRESSES. OUR GOAL IS TO UNDERSTAND HOW NEWLY-DISCOVERED PROTEINS THAT ARE OVERPRODUCED IN AD, CAN ALTER THE BRAIN TO DISRUPT COMMUNICATION BETWEEN NEURONS TO CAUSE PROBLEMS WITH MEMORY. BY UNDERSTANDING CHANGES BEHIND MEMORY LOSS IN ALZHEIMER'S, WE CAN BEGIN TO FORMULATE STRATEGIES TO RESTORE NEURONAL CONNECTIONS AND MEMORIES IN AGED AD PATIENTS. FOR MORE INFORMATION, VISIT THE

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018214F

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MICKAEL AUDRAIN, PHD, ENTITLED: (A2018253F) MICROGLIAL TYROBP INVOLVEMENT IN TAU PROPAGATION AND ASSOCIATED INFLAMMATION. INVESTIGATOR'S SUMMARY: NEUROINFLAMMATION IN THE BRAIN HAS CAUSES SUCH AS NEURODEGENERATIVE DISEASES INCLUDING DISEASES CALLED "TAUOPATHIES". CELLS CALLED "MICROGLIA" ARE THE RESIDENT "GARBAGE DISPOSAL CELLS" OF THE BRAIN AND THEREBY PLAY KEY ROLES IN ANY INFLAMMATORY PROCESSES. USING A NOVEL MULTISCALE COMPUTATIONAL APPROACH, A TEAM FROM MOUNT SINAI IDENTIFIED TYROBP AS A CAUSAL REGULATOR CONTROLLING THE GARBAGE DISPOSAL ACTIONS OF MICROGLIA. TO ELUCIDATE THE ROLE OF TYROBP IN TAUOPATHIES, WE GENERATED NEW GENETICALLY MANIPULATED TAUOPATHY MODEL MICE THAT ARE RENDERED DEFICIENT FOR TYROBP. CHARACTERIZATION OF THESE MICE WILL HELP TO DETERMINE HOW TYROBP MODIFY INFLAMMATION AND THE TAUOPATHY PROGRESSION AND THEREBY GREATLY INFLUENCE THIS FIELD OF RESEARCH. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018253F

NAME OF ORGANIZATION OR GOVERNMENT: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY WEIWEI FAN, PHD, ENTITLED: (A2018325S) TARGETING PPAR DELTA IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: PPAR DELTA IS A PROTEIN THAT IS PRESENT IN THE BRAIN. IT IS SUGGESTED TO HAVE IMPORTANT FUNCTIONS IN BRAIN. THIS PROPOSAL WILL HELP US UNDERSTAND ITS EXACT FUNCTIONS IN BRAIN. I WILL ALSO TEST WHETHER WE CAN TARGET PPAR DELTA TO TREAT ALZHEIMER'S DISEASE (AD). FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018325S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CELESTE KARCH, PHD, ENTITLED: (A2018349S) CXCR4 AS A MODIFIER OF TAU AGGREGATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: SEVERAL LINES OF EVIDENCE SUGGEST THAT INFLAMMATION AND ALTERED FUNCTION OF THE CELL TYPES IN THE BRAIN INVOLVED IN INFLAMMATION, SUCH AS MICROGLIA, REPRESENTS AN EARLY AND CRITICAL DRIVER OF ALZHEIMER'S DISEASE (AD). OUR GROUP HAS RECENTLY SHOWN THAT A CHEMOKINE RECEPTOR CXCR4 FOUND IN THE CELL TYPES THAT MEDIATE INFLAMMATION IN THE BRAIN, SUCH AS MICROGLIA, CONTRIBUTE TO TAUOPATHIES SUCH AS PROGRESSIVE SUPRANUCLEAR PALSY, FRONTOTEMPORAL DEMENTIA, CORTICOBASAL DEGENERATION, AND ALZHEIMER'S DISEASE. THE OBJECTIVE OF THIS STUDY IS TO BEGIN TO DETERMINE HOW CXCR4 DRIVES AD. TOGETHER, THE FINDINGS FROM THIS STUDY WILL DEFINE THE FUNCTION OF A NEW GENE THAT INCREASES RISK FOR AD AND OTHER TAUOPATHIES AND WILL SHED LIGHT ON ITS ROLE IN DISEASE PROCESSES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018349S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ALEX SMITH, PHD, ENTITLED: (A2018351S) AQUAPORIN-4 MISLOCALIZATION AND GLUCOSE HYPOMETABOLISM IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE HEALTHY BRAIN CONSUMES LARGE AMOUNTS OF ENERGY, TEN TIMES AS MUCH AS OTHER SIMILARLY SIZED REGIONS OF THE BODY, BUT IN ALZHEIMER'S DISEASE (AD) THE SUPPLY OF ENERGY RICH SUGAR FROM THE BLOOD TO BRAIN IS REDUCED; IT IS NOT KNOWN WHY THIS HAPPENS. BLOOD VESSELS IN THE BRAIN ARE SURROUNDED BY CELLS THAT CONTAIN A VERY LARGE AMOUNT OF A PROTEIN

CALLED AQUAPORIN-4 THAT WE THINK IS INVOLVED IN REGULATING HOW TIGHTLY THESE CELLS SURROUND THE VESSELS. IN AD, THE AMOUNT OF AQUAPORIN-4 AROUND VESSELS IS REDUCED AND WE BELIEVE THIS CAUSES THE CELLS TO SWELL AROUND THE VESSELS, BLOCKING SUGAR FROM GETTING INTO THE BRAIN. WE PROPOSE TO DO EXPERIMENTS THAT WILL TEST THIS IDEA AND CONSIDER NEW THERAPIES TO REMOVE THE BLOCK FOR SUGAR TRANSPORT INTO BRAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018351S

NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY WEI CAO, PHD, ENTITLED: (A2018377S) ROLE OF TYPE I INTERFERON IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS A DEVASTATING DISEASE WITH NO CURE. OFTEN, THE BRAINS OF AD PATIENTS HAVE ONGOING INFLAMMATION THAT FUELS THE DISEASE. THIS PROPOSAL STUDIES A NEW FAMILY OF CYTOKINE WHICH WE RECENTLY DETECTED IN AD BRAINS. AS A GOAL, WE HOPE NOT ONLY TO OBTAIN KNOWLEDGE ON HOW INFLAMMATION WORSENS AD BUT ALSO TO IDENTIFY TARGETS FOR EFFECTIVE TREATMENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018377S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSHUA GRILL, PHD, ENTITLED: (A2018405S) IMPROVING RECRUITMENT TO PRODROMAL ALZHEIMER'S DISEASE CLINICAL TRIALS. INVESTIGATOR'S SUMMARY: THE SINGLE GREATEST BARRIER TO ADVANCES IN ALZHEIMER'S DISEASE TREATMENT IS POOR RECRUITMENT TO CLINICAL TRIALS OF PROMISING THERAPIES. MOST OF THESE CLINICAL TRIALS NOW ENROLL PATIENTS WITH MILD COGNITIVE IMPAIRMENT. THIS PROJECT WILL IDENTIFY THE CHALLENGES TO ENROLLING THESE PATIENTS

IN CLINICAL TRIALS AND DEVELOP METHODS TO IMPROVE RECRUITMENT TO THESE CRITICAL STUDIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018405S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JEFFERY VANCE, MD, PHD, ENTITLED: (A2018425S) IDENTIFYING A PROTECTIVE VARIANT(S) FOR THE APOE E4 ALLELE. INVESTIGATOR'S SUMMARY: APOE IS A GENE THAT IS THE STRONGEST RISK FACTOR FOR ALZHEIMER'S DISEASE (AD), BUT AFRICAN CARRIERS OF THE RISK FORM OF APOE GET MUCH LESS AD THAN EUROPEAN CARRIERS OF THE SAME FORM OF THE GENE. WE HAVE LOCALIZED THE AREA ON THE CHROMOSOME THAT CONTAINS THE DNA CHANGE THAT IS LOWERING THE RISK FOR AD INAFRICANS. USING DNA SEQUENCE DATA FROM DIFFERENT POPULATIONS, COMPARING THE SEQUENCE DIFFERENCES AND THEN SEEING HOW THE DIFFERENCES AFFECT DNA FUNCTION, WE WILL CREATE A SMALL LIST OF POTENTIAL "PROTECTIVE" CHANGES, WE WILL HAVE A SMALL NUMBER OF CHANGES THAT CAN BE TESTED IN BIOLOGICAL MODELS. THE PURPOSE IS TO IDENTIFY HOW THE PROTECTIVE DNA CHANGE WORKS IN AFRICANS, AND USE THAT INFORMATION TO DEVELOP A DRUG TO REDUCE THE RISK TO GET AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018425S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SARA GALLANT, PHD, ENTITLED: (A2018449F) THE LOCUS COERULEUS AND MEMORY SELECTIVITY IN AGING AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE ABILITY TO SELECTIVELY FOCUS ATTENTION ON IMPORTANT INFORMATION AND IGNORE DISTRACTION IS CRITICAL FOR OPTIMAL MEMORY PERFORMANCE. THIS ABILITY BECOMES PARTICULARLY CRITICAL WHEN WE EXPERIENCE AN ALARMING EVENT THAT

INCREASES AROUSAL LEVELS AND CONSUMES ATTENTIONAL RESOURCES. EVIDENCE SUGGESTS THAT THE PART OF OUR BRAIN THOUGHT TO INSTIGATE THESE SELECTIVITY PROCESSES, THE LOCUS COERULEUS (LC), DEGRADESIN AGING AND ALZHEIMER'S DISEASE (AD), YET LITTLE IS KNOWN ABOUT THE RELATIONSHIP BETWEEN THE LC AND COGNITIVE FUNCTION IN THESE POPULATIONS. THE GOAL OF THIS RESEARCH IS THUS TO ADDRESS A NOVEL AND CRITICAL RESEARCH QUESTION: HOW FUNCTIONING OF THE LC UNDER EMOTIONAL AROUSAL RELATES TO SELECTIVE MEMORY PROCESSES IN AGING AND AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018449F

SCHEDULE I, PART II, LINE 1, COLUMN (H):
NAME OF ORGANIZATION OR GOVERNMENT: THE RESEARCH FOUNDATION FOR SUNY ON BEHALF OF UNIVERSITY AT BUFFALO SPONSORED PROJECTS SERVICES. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SHERMALI GUNAWARDENA, PHD, ENTITLED: (A2018509S) A NOVEL THERAPEUTIC NANO-VESICLE FOR THE CLEARANCE OF AXONAL BLOCKS TO PREVENT ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WITH RISING LIFE EXPECTANCIES AND AN AGING BABY BOOMER GENERATION, ALZHEIMER'S DISEASE (AD) HAS BECOME ONE OF THE LEADING CAUSES OF DEATH IN THE U.S. TREATING AD HAS PROVEN DIFFICULT AS CURRENT TREATMENTS ARE ONLY ABLE TO TARGET THE LATE STAGE OF DISEASE WITH MANY ADVERSE SIDE EFFECTS AND CURRENTLY, THERE ARE NO CURES FOR AD. THE CHALLENGE IS TO DEVELOP TREATMENTS THAT ARE ABLE TO SPECIFICALLY TARGET AFFECTED NEURONS AT EARLY STAGES OF DISEASE INITIATION. WE WILL USE A HIGHLY INNOVATIVE APPROACH TO DEVELOP SYNTHETIC BIOMOLECULES THAT WILL DELIVER THERAPEUTICS TO SPECIFIC SITES WITHIN THE BRAIN, TO MODIFY DEFECTS THAT ACTIVATE DISEASE PATHWAYS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018509S

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FARID RAJABLI, PHD, ENTITLED: (A2018556F) EVALUATING THE ROLE OF RACE, ETHNICITY, AND GENETIC ANCESTRY IN ALZHEIMER DISEASE-ASSOCIATED GENES. INVESTIGATOR'S SUMMARY: THE STRONGEST RISK GENE IDENTIFIED FOR ALZHEIMER'S DISEASE (AD) IS APOE. HOWEVER, THIS GENE DOES NOT INCREASE THE RISK FOR AD IN EVERY ETHNIC POPULATION. FOR EXAMPLE, INDIVIDUALS WITH AN AFRICAN ETHNIC BACKGROUND DO NOT SEEM TO BE VERY AFFECTED BY THIS VARIATION. THIS IS DUE TO THE FACT THAT INDIVIDUALS FROM DIFFERENT RACES/ETHNICITIES HARBOR GENETIC DIFFERENCES AT THE SITE OF THE APOE GENE. THIS IS WHY IT IS IMPORTANT TO STUDY POPULATIONS SEPARATELY AND TO TAKE INTO ACCOUNT THEIR GENETIC BACKGROUND, ALSO CALLED LOCAL ANCESTRY WHEN ANALYZING THE GENETIC EFFECT ON THE DISEASE. WE PROPOSE TO EXPLORE THE RELATIONSHIP BETWEEN LOCAL ANCESTRY OF AFRICAN AMERICAN AND CARIBBEAN HISPANIC AND AD RISK GENES. WE WILL FACILITATE THE DISCOVERY OF ETHNIC SPECIFIC GENETIC GENES INCREASING THE RISK FOR AD. THIS APPROACH WILL ALLOW US TO MOVE A FURTHER STEP TOWARD PERSONALIZED AND PRECISION MEDICINE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018556F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JESSICA YOUNG, PHD, ENTITLED: (A2018656S) PROBING THE ROLE OF THE ENDOCYTIC NETWORK IN ALZHEIMER'S DISEASE USING HUMAN NEURONAL MODELS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS A DEVASTATING NEURODEGENERATIVE DISORDER THAT IS THE MOST COMMON CAUSE OF DEMENTIA IN THE ELDERLY AND IS A TREMENDOUS SOCIOECONOMIC BURDEN. STEM CELLS

DERIVED FROM HUMAN PATIENTS CAN HELP DISCOVER NEW THERAPEUTICS FOR AD BECAUSE INDIVIDUAL GENETIC BACKGROUND IS CAPTURED IN A DISH AND STEM CELLS CAN BE DIFFERENTIATED INTO NEURONS, A RELEVANT CELL TYPE TO ANALYZE MOLECULARFEATURES. MY PROPOSAL WILL TEST WHETHER GENES IDENTIFIED WITH AD RISK CONFER MEASURABLE LABORATORY READ-OUTS CHARACTERISTIC OF AD IN NEURONS GROWN IN THE LABORATORY. IN PARTICULAR, I WILL FOCUS ON A PARTICULAR CELLULAR PATHWAY, THE ENDOSOMAL NETWORK, WHICH MAY BECOME DYSFUNCTIONAL IN AD BEFORE AMYLOID AND TAU DEPOSITION ARE REPORTED. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018656S

NAME OF ORGANIZATION OR GOVERNMENT: REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DANIEL GESCHWIND, MD, PHD, ENTITLED: (A2018700S) A MULTI-LEVEL UNDERSTANDING OF GLIAL SIGNALING IN NEURODEGENERATIVE TAUOPATHY USING INTEGRATIVE TRANSCRIPTOMIC NETWORK ANALYSIS. INVESTIGATOR'S SUMMARY: RECENT SCIENTIFIC DISCOVERIES SUGGEST THAT MULTIPLE CELL TYPES MIGHT PARTICIPATE IN ALZHEIMER'S DISEASE AND UNDERSTANDING THE KEY PLAYERS AND THEIR EFFECTS ON DEMENTIA WOULD ADVANCE OUR ABILITY TO DESIGN NEW DRUGS AND THERAPIES. HOWEVER, THE COMPLEXITY OF BRAIN'S DIFFERENT CELL TYPES PRESENTS A UNIQUE CHALLENGE TO SCIENTIFIC INQUIRY. HERE I PROPOSE WORK TO BRIDGE THE DIVIDE BY USING CUTTING EDGE TECHNOLOGY TO PROFILE THE DIFFERENT CELLS OF THE DEMENTIA BRAIN AT UNPRECEDENTED RESOLUTION. THE RESULTS OF THIS WORK WILL BE NEW CANDIDATE DRUG TARGETS FOR DEMENTIA AND A NEW APPROACH FOR STUDYING COMPLEX BRAIN DISEASES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018700S

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHARLES GLABE, PHD, ENTITLED: (A2018718S) NECROPTOSIS AND NEURODEGENERATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: IN THE CONTINUOUSLY AGING, MODERN POPULATION OF DEVELOPING COUNTRIES, UNDERSTANDING OF THE MECHANISMS THAT CONTRIBUTE TO THE DEVELOPMENT TO AGE-RELATED, NEURODEGENERATIVE DISEASES IS OF THE UTMOST IMPORTANCE. DISTURBANCES IN CELLULAR REGULATION, E.G., ON THE LEVEL OF THE SIGNALING OF CELL DEATH MIGHT SIGNIFICANTLY CONTRIBUTE TO THE OCCURRENCE, PROPAGATION AND SEVERITY OF PATHOPHYSIOLOGICAL STATES SUCH AS THE OCCURRENCE AND DEVELOPMENT OF ALZHEIMER'S DISEASE (AD). ESPECIALLY, CELL DEATH PATHWAYS THAT ARE INVOLVED IN THE PROGRESSION OF THE INFLAMMATORY RESPONSE, ONE OF THE HALLMARKS OF AD, ARE OF HIGHEST INTEREST. IMPORTANTLY, DETAILED KNOWLEDGE ABOUT THIS SPECIFIC TYPE OF INFLAMMATORY CELL DEATH PATHWAY, ITS SPATIAL AND TEMPORAL DISTRIBUTION IN AD BRAINS MIGHT ALLOW US TO IDENTIFY POTENTIAL THERAPEUTIC STRATEGIES TO PREVENT NEURODEGENERATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2018718S

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC JACKSONVILLE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NA ZHAO, MD, PHD, ENTITLED: (A2018777F) EFFECTS OF APOE ISOFORMS ON BRAIN INSULIN SIGNALING AND ENERGY METABOLISM IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: STUDIES SHOW THAT HAVING APOLIPOPROTEIN E4 (APOE4) GENE INCREASES A PERSON'S RISK FOR ALZHEIMER'S DISEASE (AD). THE PERSONS, WHO HAVE AD AND/OR APOE4 GENE, HAVE PROBLEMS WITH OBTAINING ENERGY IN THEIR BRAIN. INSULIN IS A DRUG THAT COULD HELP WITH THE PROCESS OF BREAKING DOWN SUBSTANCES IN THE CELLS TO OBTAIN ENERGY. THUS WE WOULD

LIKE TO USE ANIMAL MODELS TO LOOK AT WHETHER INSULIN CAN RESCUE THE BRAIN ENERGY IN THE ANIMALS THAT HAS AD AND/OR APOE4 GENE. OUR FINDINGS WILL BE VERY USEFUL IN UNDERSTANDING HOW APOE4 IMPAIRS BRAIN HEALTH AND HOW WE CAN USE INSULIN AS AN EFFECTIVE TREATMENT FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2018777F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ZHUOHAO HE, PHD, ENTITLED: (A2018802S) STUDY AN ALZHEIMER'S DISEASE SPECIFIC TAU STRAIN. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS DEFINED BY THE PRESENCE OF AMYLOID PLAQUES AND TAU TANGLES IN THE BRAIN ASSOCIATED WITH MEMORY LOSS; HOWEVER, A SIGNIFICANT NUMBER OF PATIENTS WITH AD HAVE NON-MEMORY SYMPTOMS, SUCH AS LANGUAGE OR VISUOSPATIAL IMPAIRMENT. THE UNDERLYING BIOLOGY OF THESE NON-AMNESTIC AD PATIENTS IS UNDERSTUDIED. FURTHER UNDERSTANDING OF THE GENETIC INFLUENCE AND PROGRESSION OF TAU PATHOLOGY IN NON-AMNESTIC AD WILL IMPROVE THE DIAGNOSIS OF PATIENTS WHO MAY BENEFIT FROM EMERGING THERAPIES THAT AIM TO HALT OR SLOW THE PROGRESSION OF PLAQUES AND TANGLES IN THE BRAIN AND ALSO IDENTIFY NEW GENETIC TARGETS FOR DRUG DEVELOPMENT IN AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2018802S

NAME OF ORGANIZATION OR GOVERNMENT: THE TRUSTEES OF COLUMBIA UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OTTAVIO ARANCIO, MD, PHD, ENTITLED: (A2018816S) TAU-INDUCED DAMAGE AT HIPPOCAMPAL TRIPARTITE SYNAPSES. INVESTIGATOR'S SUMMARY: THE COGNITIVE AND BEHAVIORAL SYMPTOMS THAT CHARACTERIZE ALZHEIMER'S DISEASE (AD) ARE

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

THOUGHT TO RESULT FROM IMPAIRED COMMUNICATION BETWEEN NEURONS IN THE BRAIN AT CONNECTIONS CALLED SYNAPSES. TOXIC FORMS OF A PROTEIN CALLED TAU PLAY A CENTRAL ROLE IN AD AND OTHER NEURODEGENERATIVE CONDITIONS, AND RECENT DATA SHOW THAT TAU CAN INTERFERE WITH SYNAPSES IN MULTIPLE WAYS. THESE OBSERVATIONS GREATLY COMPLICATE EFFORTS TO TREAT AD BY BLOCKING THE PATHOLOGICAL ACTIONS OF TAU. THE GOAL OF THIS PROJECT IS TO BETTER UNDERSTAND HOW TAU INTERFERES WITH SYNAPTIC FUNCTION SO THAT WE CAN DEVELOP EFFECTIVE STRATEGIES TO BLOCK THE IMPAIRMENTS IT CAUSES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2018816S

SCHEDULE I, PART II, LINE 1, COLUMN (H):

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JEREMY STRAIN, PHD, ENTITLED: (A2018817F) WHITE MATTER HYPERINTENSITY LOCALIZATION AND SEVERITY IN ASSOCIATION WITH PET TAU IN ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: EACH OF THE AIMS OF THIS PROJECT ARE DIRECTED AT UNDERSTANDING HOW AND WHERE STRUCTURAL CONNECTIONS IN THE BRAIN ARE DAMAGED IN TWO VARIANTS OF ALZHEIMER'S DISEASE (AD). WE DISCUSS TWO KNOWN CAUSES OF WHITE MATTER DAMAGE COMMONLY SEEN IN THIS POPULATION THAT CAN BE DETECTED BY COMBINING DIFFERENT NEUROIMAGING AND ANALYTICAL TECHNIQUES THAT WE ARE CAPABLE OF PERFORMING. THIS WILL IMPROVE OUR UNDERSTANDING OF THE BIOLOGICAL CORRELATES THAT CHARACTERIZE THIS DISEASE AND THE SUBTLE DIFFERENCES IN PROGRESSION BETWEEN THESE TWO TYPES OF AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2018817F

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT

SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY EDOARDO MARCORA, PHD, ENTITLED: (A2017458S) UNDERSTANDING THE ROLE OF APOLIPOPROTEIN E IN MICROGLIA. INVESTIGATOR'S SUMMARY: SUPPLEMENTAL FUNDING ON AWARD WITH NON-TECH ABSTRACT: HUMAN GENETIC STUDIES STRONGLY POINT TO APOLIPOPROTEIN E (APOE) AND MICROGLIA (THE IMMUNE CELLS OF THE BRAIN) AS, RESPECTIVELY, THE MOST IMPORTANT GENE AND CELL TYPE IN THE CHAIN OF EVENTS THAT LEADS TO ALZHEIMER'S DISEASE (AD), A COMMON DISORDER IN THE ELDERLY IN WHICH THE BRAIN IS DAMAGED AND MEMORIES FALTER. IN NORMAL CONDITIONS, MICROGLIAL CELLS DO NOT MAKE APOE; HOWEVER, IN DISEASE CONDITIONS, THEY SENSE THE BRAIN DAMAGE AND RESPOND BY CHURNING OUT APOE. IT IS UNCLEAR WHY THIS OCCURS AND THE GOAL OF THIS PROJECT IS TO ANSWER THIS QUESTION BY INVESTIGATING WHAT HAPPENS TO MICE WITHOUT THE APOE GENE IN THEIR MICROGLIA AFTER THEY EXPERIENCE BRAIN STRESS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2017458S

NAME OF ORGANIZATION OR GOVERNMENT: HUMAN COMPUTATION INSTITUTE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PIETRO MICHELUCCI, PHD, ENTITLED: (CA2017606) CROWD POWERED MICROVASCULAR MODELING PHASE 2. INVESTIGATOR'S SUMMARY: THE CENTRAL AIM OF THIS PROJECT IS TO ACCELERATE RESEARCH INTO POTENTIAL ALZHEIMER'S TREATMENTS TARGETING THE BRAIN MICROVASCULATURE. THIS WILL BE DONE THROUGH OUR EYEONALZ PROJECT, WHICH USES CITIZEN SCIENCE (A FORM OF CROWDSOURCING). WITHOUT THIS CROWDSOURCED PROGRAM, THE SAME RESEARCH WOULD OTHERWISE TAKE DECADES TO COMPLETE. OUR APPROACH IS TO TRANSFORM A TIME-CONSUMING LABORATORY TASK INTO AN ONLINE GAME THAT ANYONE CAN PLAY. PROJECT SUCCESS DEPENDS UPON RECRUITING AND SUSTAINING AN ACTIVE POPULATION OF PUBLIC VOLUNTEERS AND IMPROVING OUR ABILITY TO EXTRACT RESEARCH VALUE FROM EACH PARTICIPANT.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

WE ALSO HOPE THIS PROJECT PROVIDES A HANDS-ON WAY FOR PEOPLE AFFECTED BY ALZHEIMER'S DISEASE (AD) TO MAKE AN IMPACT ON THEIR OWN FUTURE OR THAT OF A LOVED ONE, AND THAT IT EDUCATES THE GENERAL PUBLIC ABOUT THE DISEASE. TO LEARN MORE ABOUT EYESONALZ, VISIT WWW.EYESONALZ.COM.

NAME OF ORGANIZATION OR GOVERNMENT: HUMAN COMPUTATION INSTITUTE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PIETRO MICHELUCCI, PHD, ENTITLED: (CA2016629) CROWD-POWERED MICROVASCULAR MODELING. INVESTIGATOR'S SUMMARY: ADDITIONAL FUNDING FOR THE FY16 AWARD: CORNELL UNIVERSITY RESEARCHERS HAVE MADE BREAKTHROUGH DISCOVERIES IN UNDERSTANDING THE ROLE OF BRAIN BLOOD FLOW IN ALZHEIMER'S DISEASE (AD), BUT MORE EVIDENCE IS NEEDED TO ESTABLISH WHETHER FREEING STALLED CAPILLARIES MIGHT RESULTS IN A POSSIBLE TREATMENT APPROACH. THE PROBLEM IS THAT IT TAKES AN ENTIRE YEAR TO ANALYZE THE DATA NEEDED TO ANSWER EACH RESEARCH QUESTION, AND PROGRESS TO DATE HAS BEEN VERY SLOW. "STALL CATCHERS" IS A CITIZEN SCIENCE RESEARCH PROJECT DEVELOPED BY THE HUMAN COMPUTATION INSTITUTE IN COLLABORATION WITH CORNELL INVESTIGATORS CHRIS SCHAFFER AND NOZOMI NISHIMURA AIMED AT SPEEDING UP CORNELL'S DATA ANALYSIS BY TURNING IT INTO AN ONLINE GAME THAT ANYONE CAN PLAY. OUR PHASE I GOAL IS TO SEE WHETHER THOUSANDS OF PUBLIC PARTICIPANTS CAN ANALYZE THE RESEARCH DATA JUST AS ACCURATELY AS LAB EXPERTS, BUT BY WORKING TOGETHER, DO IT MUCH FASTER. IN PHASE II, WE WILL APPLY THE VALIDATED CROWD ENGINE TO NEW EXPERIMENTAL DATA TO SEE IF WE CAN REDUCE THE TIME TO A TREATMENT TARGET FROM DECADES TO JUST A FEW YEARS. THIS IS THE FIRST CITIZEN SCIENCE PROJECT SUPPORTING ALZHEIMER'S DISEASE (AD) RESEARCH. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2016629

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE. (H) PURPOSE OF GRANT: (CA2017563) MOLECULAR NEURODEGENERATION JOURNAL. WE PARTNER WITH BIOMED CENTRAL'S OPEN ACCESS JOURNAL,MOLECULAR NEURODEGENERATION(MN), WHICH IS THE OFFICIAL JOURNAL OF BRIGHTFOCUS. THE OPEN ACCESS PUBLISHING MODEL PROVIDES FREE ARTICLES TO THE GENERAL PUBLIC, AS WELL AS SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE PRACTITIONERS. MN PUBLISHES PEER-REVIEWED, ORIGINAL SCIENTIFIC RESEARCH ON THE CAUSES OF NEURODEGENERATIVE DISEASES, SUCH AS ALZHEIMER'S OR PARKINSON' AND ON THE PRE-CLINICAL TESTING OF POTENTIAL THERAPIES FOR THESE DEVASTATING DISEASES. MN HAS AN IMPACT SCORE OF 6.78, MEANING THE JOURNAL IS NOW THE HIGHEST RANKING OPEN ACCESS NEUROSCIENCE JOURNAL IN THE JOURNAL CITATION REPORTS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF DENVER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANN CHARLOTTE GRANHOLM-BENTLEY, PHD, ENTITLED: (CA2018010) INTERNATIONAL BRAIN BANK FOR DOWN SYNDROME-RELATED ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE LONG-TERM GOAL OF THIS PROJECT IS TO DETERMINE THE NEUROBIOLOGICAL MECHANISMS UNDERLYING ALZHEIMER'S DISEASE IN DOWN SYNDROME(DS) PRIOR TO THE ONSET OF DEMENTIA. THE FIRST AIM OF THIS PROJECT IS TO BANK AND DISTRIBUTE HIGH QUALITY BIOLOGICAL RESEARCH SAMPLES, LINKED TO CLINICAL DATA, FROM BOTH NATIONAL AND INTERNATIONAL COHORTS OF PEOPLE WITH DOWN SYNDROME AND DEMENTIA, AND DEVELOP AN INTERNATIONALLY ACCEPTED NEUROPATHOLOGICAL STAGING PROTOCOL FOR THIS VULNERABLE POPULATION. THE SECOND GOAL IS TO MAKE THESE SAMPLES AVAILABLE TO FACILITATE COLLABORATIVE RESEARCH STUDIES INTO BIOLOGICAL MECHANISMS OF DS-RELATED AD THAT MAY ALSO BE TRANSLATABLE TO THE GENERAL POPULATION WITH AD. THE THIRD GOAL IS TO PERFORM COLLABORATIVE RESEARCH STUDIES ON EARLY EVENTS

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

IN THE AD PROCESS IN PEOPLE WITH INTELLECTUAL DISABILITIES, COLLABORATING WITH MANY DIFFERENT RESEARCH GROUPS IN THE USA AND EUROPE, WITH THE SPECIFIC PURPOSE OF DEVELOPING NEW THERAPEUTIC TARGETS FOR THOSE WITH DS AND DEMENTIA, AS WELL AS FOR THOSE WITH ALZHEIMER'S DISEASE AND OTHER DEMENTIAS IN THE GENERAL POPULATION. THIS PROJECT IS UNIQUE IN THAT IT IS THE ONLY FUNDED BIOBANK CONSORTIUM IN THE US FOCUSED ON PEOPLE WITH INTELLECTUAL DISABILITIES AS THEY AGE AND ACCRUE ALZHEIMER'S DISEASE AND OTHER DEMENTIAS. THIS POPULATION HAS INCREASED THEIR LIFE SPAN SIGNIFICANTLY DURING THE LAST FEW DECADES, BUT FEW STUDIES HAVE BEEN FOCUSED ON STUDYING THIS MEDICALLY UNDERSTUDIED GROUP. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2018010

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARK HENKEMEYER, PHD, ENTITLED: (A2016345S) EPHB RECEPTORS: NOVEL PRO-SYNAPTIC THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: SUPPLEMENTAL ON EXISTING FY16 AWARD WITH THE FOLLOWING DESCRIPTION: ALZHEIMER'S DISEASE SLOWLY PROGRESSES AS MORE AND MORE SYNAPSES IN THE BRAIN ARE DESTROYED AND THIS CAUSES A GRADUAL DECLINE IN MEMORIES THAT INEVITABLY LEADS TO DEMENTIA AND DEATH. EPHB RECEPTORS ARE IMPORTANT PROTEINS FOR SYNAPSE FUNCTION AND HEALTH AS THEY HOLD HANDS WITH THE NMDA RECEPTOR PROTEIN TO HELP OUR BRAINS STORE MEMORIES. EPHB ALSO HAS THE UNFORTUNATE ABILITY TO HOLD HANDS WITH PLAQUE-FORMING AMYLOID-BETA (A-BETA) PEPTIDES MADE TO EVER INCREASING LEVELS IN ALZHEIMER'S DISEASE AND THIS TARGETS EPHB FOR DEGRADATION RESULTING IN A REDUCTION IN MEMORIES. USING NOVEL HIGH-THROUGHPUT SCREENS OF SMALL DRUG-LIKE CHEMICAL LIBRARIES FOR COMPOUNDS THAT

DISRUPT THE ABILITY OF EPHB TO BIND WITH A-BETA, I AIM TO DISCOVER A NEW CLASS OF MEDICINES THAT WILL HALT THE DESTRUCTION OF SYNAPSES AND AVERT MEMORY LOSS WITH DIRECT IMPLICATION FOR THE PREVENTION OF ALZHEIMER'S DISEASE.

SCHEDULE I, PART II, LINE 1, COLUMN (H):
NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JILL GOLDSTEIN, PHD, ENTITLED: (CA2018607) DEVELOPMENT OF CLINICAL ALGORITHM TO IDENTIFY RISK FOR ALZHEIMER'S DISEASE IN EARLY MIDLIFE. INVESTIGATOR'S SUMMARY: 18% OF THE U.S. IS GREATER THAN 60 YEARS OF AGE, WITH PROJECTIONS OF 25-30% BY 2050. THUS, HEALTHY AGING IS ONE OF THE MOST IMPORTANT PUBLIC HEALTH CHALLENGES OF OUR TIME. MAINTAINING INTACT COGNITIVE FUNCTION IS CRITICAL TO THAT END. MOST WORK ON COGNITIVE AGING AND ALZHEIMER'S DISEASE (AD) BEGINS WITH PEOPLE GREATER THAN 65 YEARS. HOWEVER, WE NOW KNOW THAT SUCCESSFUL TREATMENT LIKELY SHOULD BEGIN IN EARLY MIDLIFE. WE HAVE AN UNPRECEDENTED OPPORTUNITY TO CREATE A "LIVING LABORATORY" FOR THE IDENTIFICATION OF BIOMARKERS AND TARGETS FOR THERAPEUTICS TO ENHANCE ONE'S RESILIENCE TO AGING AND PREVENT DECLINE IN COGNITION AND OTHER ORGAN FUNCTIONS BEGINNING IN EARLY MIDLIFE. WE ARE LEVERAGING THE PARTNERS HEALTHCARE BIOBANK BY CREATING THE BWH HEALTHY AGING TRANSLATIONAL COHORT (HATCH). THIS COHORT IS BEING CREATED AS A PLATFORM THAT WOULD PROVIDE A RESEARCH AND CLINICAL INFRASTRUCTURE FOR THE STUDY OF DISORDERS OF AGING, CREATING SUBSTANTIAL OPPORTUNITIES INVESTIGATORS AND INDUSTRY PARTNERS WITH CRITICAL IMPLICATIONS FOR PRECISION MEDICINE AND HEALTHCARE UTILIZATION. HERE, WE PROPOSE TO DEVELOP AND VALIDATE A QUANTITATIVE TOOL, A CLINICAL RISK ALGORITHM, THAT INTEGRATES POLYGENIC-CLINICAL-PHYSIOLOGICAL AND NEURAL PHENOTYPING

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

TO IDENTIFY IN EARLY MIDLIFE (AGES 45-65 YEARS) PEOPLE WHO MAY ALREADY HAVE ACCUMULATED AMYLOID PATHOLOGY AND ARE AT HIGHEST RISK FOR COGNITIVE DECLINE AND AD LATER IN LIFE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2018607

NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH AND SCIENCE UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BENJAMIN SIVYER, PHD, ENTITLED: (G2018011) AXO-SOMATIC AND DENDRITIC PLASTICITY IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A DISEASE THAT CAUSES THE DEATH OF RETINAL CELLS THAT COMMUNICATE WITH THE BRAIN. WE HAVE LITTLE KNOWLEDGE OF HOW THIS GRADUAL PROCESS OF CELL DEATH IS INFLUENCED BY OTHER CELLS IN THE RETINA AND GAINING INSIGHT INTO THESE MECHANISMS WILL ALLOW US TO DEVELOP NEW WAYS TO TREAT GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018011

NAME OF ORGANIZATION OR GOVERNMENT: CASE WESTERN RESERVE UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JESSICA COOKE BAILEY, PHD, ENTITLED: (G2018042) GLAUCOMA EVALUATION IN THE AMISH. INVESTIGATOR'S SUMMARY: WE KNOW THAT GENETICS AND ENVIRONMENT PLAY A ROLE IN GLAUCOMA RISK, BUT MOST OF THE PEOPLE WHO HAVE BEEN STUDIED ARE DIFFERENT ON MANY LEVELS INCLUDING (I) THE SPECIFIC TYPE OF GLAUCOMA THEY HAVE, (II) THEY ARE UNRELATED AND THEREFORE THEIR GENETIC BACKGROUNDS ARE COMPLICATED, AND (III) THEIR ENVIRONMENTAL EXPOSURES VARY WIDELY. WE WANT TO STUDY GLAUCOMA IN THE AMISH, A GROUP THAT IS ESSENTIALLY A VERY LARGE FAMILY, BECAUSE (I) THEY ARE MORE LIKELY TO HAVE THE SAME TYPE OF GLAUCOMA, (II) THEIR GENETIC BACKGROUNDS ARE MORE RELATED, AND THEREFORE THERE IS LESS CONFUSING GENETIC 'NOISE' TO SIFT

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

THROUGH WHEN PERFORMING GENETIC ANALYSES, AND (III) THEY HAVE FAIRLY UNIFORM LIFESTYLES AND THEREFORE THERE ENVIRONMENTAL EXPOSURES ARE MORE SIMILAR TO ONE ANOTHER AS COMPARED TO OTHER GROUPS IN WHICH GLAUCOMA HAS BEEN STUDIED. WE WILL EXAMINE THEIR EYES, GET DETAILED MEDICAL HISTORIES, ASK MANY QUESTIONS ABOUT THEIR ENVIRONMENTAL EXPOSURES AND LIFESTYLE CHOICES, AND GET BLOOD SO WE CAN STUDY THEIR GENETICS. WE THINK THAT BY UNDERSTANDING GLAUCOMA RISK IN THE AMISH, WE CAN LEARN MORE ABOUT THE GENES AND PATHWAYS THAT INFLUENCE THIS DISEASE AND APPLY THIS KNOWLEDGE TO BETTER INFORM PREVENTATIVE AND TREATMENT STRATEGIES RELEVANT TO THE MILLIONS OF PEOPLE THROUGHOUT THE WORLD WHO WILL LIKELY DEVELOP GLAUCOMA WITHOUT NEW WAYS OF UNDERSTANDING DISEASE RISK AND PREVENTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018042

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SUCHISMITA ACHARYA, PHD, ENTITLED: (G2018056) BI-FUNCTIONAL MOLECULE FOR GLAUCOMATOUS OPTIC NEUROPATHY. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A BLINDING DISEASE AND IT IS ESTIMATED THAT OVER 76 MILLION PEOPLE WILL BE AFFECTED BY THIS DISEASE BY 2020. IT IS ASSOCIATED WITH ELEVATED EYE PRESSURE, PROGRESSIVE DEATH OF RETINAL GANGLION CELLS (RGCS) AS WELL AS DEGENERATION OF OPTIC NERVE HEAD (WHICH CONNECTS THE BRAIN TO THE EYE). NITRIC OXIDE (A SMALL GASEOUS MOLECULE KNOWN TO ACT AS ANTI-OXIDANT, A KEY PLAYER IN RELAXING THE SMOOTH MUSCLE CELLS AND PROTECTING DAMAGING BLOOD VESSELS) HAS POTENTIAL TO REDUCE EYE PRESSURE WITH HIGH POSSIBILITY OF PROTECTING THE NEURAL CELLS, HOWEVER, FREE RADICALS GENERATED DURING OPTIC NEUROPATHY MAY DEPLETE THE NITRIC OXIDE BIOAVAILABILITY. OUR GROUP IS WORKING ON DISCOVERING SUCH

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

MULTI-FUNCTIONAL SMALL MOLECULES WHICH WILL DECREASE EYE PRESSURE AND PROTECT NEURONS, RETINAL GANGLION CELLS FROM DEATH THAT MAY BE USED FOR GLAUCOMA TREATMENT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018056

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF HOUSTON. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JASON PORTER, PHD, ENTITLED: (G2018061) HIGH-RESOLUTION IMAGING OF SUPERFICIAL RETINAL VASCULAR CHANGES IN EXPERIMENTAL GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE LEADING CAUSE OF IRREVERSIBLE BLINDNESS WORLDWIDE (ESTIMATED TO AFFECT OVER 60 MILLION PEOPLE) AND IS GENERALLY CONSIDERED TO BE CAUSED BY THE DAMAGE OF RETINAL GANGLION CELL AXONS AND THE DEATH OF RETINAL GANGLION CELLS. PREVIOUS STUDIES SUPPORT THE IDEA THAT THE LOSS OF RADIAL PERIPAPILLARY CAPILLARIES MAY PLAY AN IMPORTANT ROLE IN AXONAL DEGENERATION IN GLAUCOMA. THIS PROPOSAL WILL USE HIGH-RESOLUTION IN VIVO IMAGING TO BETTER CLARIFY CHANGES IN THE RADIAL PERIPAPILLARY CAPILLARIES AND OPTIC NERVE HEAD IN RELATION TO NEURONAL DAMAGE IN LIVING EYES WITH EXPERIMENTAL GLAUCOMA. THE RESULTS OF THE PROPOSED WORK MAY AID IN EARLIER DIAGNOSIS AND MANAGEMENT OF THIS DISEASE BY PROVIDING AN EARLIER STRUCTURAL MARKER FOR DETECTING GLAUCOMATOUS DAMAGE COMPARED TO CURRENT CLINICAL MEASURES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018061

NAME OF ORGANIZATION OR GOVERNMENT: SUNY HEALTH SCIENCE CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JOHN DANIAS, MD, PHD, ENTITLED: (G2018077) NEXT GENERATION EXPERIMENTAL GLAUCOMA MODEL. INVESTIGATOR'S SUMMARY: HIGH PRESSURE INSIDE THE EYE IS THE MAIN RISK FACTOR FOR DEVELOPMENT AND PROGRESSION OF GLAUCOMA. WE WILL DEVELOP A

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

NEW EXPERIMENTAL MODEL OF GLAUCOMA THAT ACCURATELY MIMICS WHAT HAPPENS IN THE HUMAN EYE WHEN IT IS EXPOSED TO HIGH PRESSURE. WE WILL USE THIS MODEL TO DETERMINE AND QUANTIFY THE RATE OF DAMAGE CAUSED BY GLAUCOMA TO OCULAR STRUCTURES AND THE VISUAL FUNCTION AND DETERMINE THE BIOMECHANICAL RESPONSE OF EYE TISSUES TO HIGH PRESSURE IN THE EYE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018077

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY F. KENT HAMRA, PHD, ENTITLED: (G2018080) TRANSGENIC BROWN NORWAY RATS FOR GLAUCOMA RESEARCH. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE WORLD'S LEADING CAUSE OF IRREVERSIBLE BLINDNESS. THIS BRIGHTFOCUS FOUNDATION RESEARCH GRANT WILL APPLY NEW TECHNOLOGIES TO CREATE BROWN NORWAY RAT MODELS THAT DEVELOP HUMAN-LIKE FORMS OF GLAUCOMA. "HUMANIZED" RAT MODELS GENERATED BY THIS PROJECT WILL BE USED BY EYE RESEARCHERS TO FIND NEW THERAPIES THAT SPECIFICALLY NEUTRALIZE THE HUMAN GLAUCOMA-CAUSING GENES, THEREBY PREVENTING GLAUCOMA IN THE RATS. THERAPIES THAT PREVENT GLAUCOMA FROM DEVELOPING IN THE HUMANIZED RAT GLAUCOMA MODELS WILL PROVIDE CANDIDATE THERAPEUTICS FOR BATTLING GLAUCOMA IN HUMANS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018080

SCHEDULE I, PART II, LINE 1, COLUMN (H):

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MONICA JABLONSKI, PHD, ENTITLED: (G2018116) NEW GLAUCOMA MODELS MINED FROM AN INBRED GENETIC REFERENCE PANEL. INVESTIGATOR'S SUMMARY:

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

MILLIONS OF PEOPLE ARE AFFECTED BY GLAUCOMA AND SOME LOSE THEIR VISION DUE TO THIS DISEASE. TO DEVELOP NEW DRUGS TO TREAT GLAUCOMA OR TO UNDERSTAND WHY GLAUCOMA CAUSES VISION LOSS, IT IS IMPORTANT TO HAVE ACCURATE MODELS OF THE DISEASE. UNFORTUNATELY, THERE ARE NOT ENOUGH MODELS AVAILABLE THAT TRULY REFLECT THE HUMAN DISEASE. WE HOPE TO CHANGE THAT. IN OUR STUDY, WE WILL IDENTIFY AND CHARACTERIZE NEW GLAUCOMA MODELS THAT SHARE THE DISEASE PHENOTYPE OF HUMANS. THESE MODELS WILL BE A VERY USEFUL RESOURCE FOR ALL VISION SCIENTISTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/G2018116

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY XIANGRUN HUANG, PHD, ENTITLED: (G2018148) SPECTRAL CONTRAST OF RETINAL NERVE FIBER LAYER REFLECTANCE: A NEW MEANS FOR SENSITIVE DETECTION OF GLAUCOMATOUS DAMAGE. INVESTIGATOR'S SUMMARY: GLAUCOMA, A LEADING CAUSE OF BLINDNESS WORLDWIDE, DAMAGES A TYPE OF NEURONAL CELLS CALLED RETINAL GANGLION CELLS AND THEIR NERVE FIBERS, KNOWN AS AXONS, IN THE EYE. EARLY DETECTION OF ABNORMITIES OF THE NERVE FIBERS CAN PERMIT EARLY MEDICAL INTERVENTION TO PREVENT VISION LOSS OF GLAUCOMATOUS PATIENTS. THE PROPOSED RESEARCH WILL DEVELOP A NEW OPTICAL IMAGING METHOD THAT DETECTS ABNORMITIES OF THE LIGHT REFLECTED BY THE NERVE FIBERS. THE NEW APPROACH CAN PROVIDE SENSITIVE DETECTION OF THE ABNORMITIES THAT OCCUR AT EARLY STAGES OF GLAUCOMA. IF SUCCESSFUL, THE DEVELOPED METHODS CAN BE READILY TRANSLATED TO CLINICAL USE AND PROVIDE CLINICIANS WITH A NEW MEANS TO SENSITIVELY DETECT EARLY GLAUCOMATOUS DAMAGE, OPENING AN EARLY THERAPEUTIC WINDOW FOR THE PREVENTION OF GLAUCOMATOUS DAMAGE AND VISION LOSS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

WWW.BRIGHTFOCUS.ORG/GRANT/G2018148

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ROBERT W. NICKELLS, PHD, ENTITLED: (G2018166) THE PATHOLOGICAL CONTRIBUTION OF CELL ADHESION DISRUPTION IN RGC DEATH. INVESTIGATOR'S SUMMARY: IN ORDER FOR CELLS TO FUNCTION NORMALLY THEY NEED TO MAKE CONNECTIONS WITH OTHER CELLS AND WITH THEIR ENVIRONMENT. BREAKING THESE CONNECTIONS WILL CAUSE DEATH. WE BELIEVE THAT RETINAL GANGLION CELLS LOSE THESE CONNECTIONS AFTER OPTIC NERVE DAMAGE AND THAT THIS MAY BE ONE OF THE IMPORTANT INITIATORS OF THEIR DEATH IN GLAUCOMA. UNDERSTANDING THE IMPORTANCE OF THE LINK BETWEEN GANGLION CELL CONNECTIONS AND GANGLION CELL DEATH MAY HELP US DEVELOP WAYS TO PREVENT THIS PATHOLOGY IN OPTIC NEUROPATHIES LIKE GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018166

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF ILLINOIS AT CHICAGO.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BIJI MATHEW, PHD, ENTITLED: (G2018168) NOVEL CELL-FREE TREATMENT OF GLAUCOMA. INVESTIGATOR'S SUMMARY: RETINAL GANGLION CELL DEATH AND AXONAL LOSS ARE HALL MARK EVENTS LEADING TO GLAUCOMA AND, NEUROPROTECTION OF RETINA BY REGENERATION, OR PREVENTION OF CELLS FROM DYING, ARE KEY FACTORS AND MAJOR PUBLIC HEALTH NECESSITIES. OUR OBJECTIVE IS TO STUDY THE USE OF EXTRACELLULAR VESICLES (EV), TINY PARTICLES SECRETED BY MESENCHYMAL STEM CELLS, AS A TREATMENT FOR GLAUCOMA INDUCED CELL DEATH. DELIVERING THE EV SPECIFICALLY INTO THE RETINA AND PROLONGING THE EFFECT, ARE MAJOR LIMITATIONS REDUCING THE TREATMENT EFFICACY. THEREFORE, OUR STUDY IS FOCUSED TO ENGINEER MODIFIED TARGETED EV FOR RETINA-SPECIFIC

NEUROPROTECTIVE ACTION FOR TREATING GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018168

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF AKRON. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ROUZBEH AMINI, PHD, ENTITLED: (G2018177) IN-VIVO ASSESSMENT OF HUMAN IRIS MECHANICAL PROPERTIES. INVESTIGATOR'S SUMMARY: THE SHAPE OF THE IRIS AND HOW IT DEFORMS IN RESPONSE TO LIGHT (I.E. PUPIL DILATION OR CONSTRICTION) ARE IMPORTANT FACTORS IN UNDERSTANDING THE MECHANISM OF GLAUCOMA. SIMILAR TO ANY OTHER TISSUE THAT DEFORMS (E.G. BLOOD VESSELS OR SKELETAL MUSCLES), IF THE IRIS IS STIFFER, IT DEFORMS DIFFERENTLY, WHICH HAS BEEN THE CASE IN SOME GLAUCOMA PATIENTS. UNLIKE PREVIOUS STUDIES, IN WHICH SURGICALLY REMOVED PIECES OF THE IRIS WERE USED FOR QUANTIFYING THE STIFFNESS, WE AIM TO COMBINE NONINVASIVE IMAGINING TECHNIQUES CURRENTLY USED IN EYE CLINICS WITH A NOVEL COMPUTER MODEL TO ESTIMATE IRIS STIFFNESS. WE ALSO AIM TO UNDERSTAND HOW STIFFENING OF THE IRIS AFFECTS THE SHAPE OF ITS COMPRISING CELLS DURING THE PUPIL'S RESPONSES TO LIGHT, BECAUSE WE BELIEVE THAT CELLULAR-LEVEL DEFORMATION IS AN IMPORTANT FACTOR IN THE REGULATION OF ACTIVITIES IN THOSE CELLS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018177

NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY YANG HU, MD, PHD, ENTITLED: (G2018183) IDENTIFY THE EFFECTORS AND REGULATORS OF ER STRESS THAT GOVERN GLAUCOMATOUS DEGENERATION. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE MOST COMMON CAUSE OF IRREVERSIBLE BLINDNESS AND WILL AFFECT MORE THAN 100 MILLION PEOPLE BETWEEN 40 TO 80 YEARS OLD BY 2040. GLAUCOMA IS CHARACTERIZED BY OPTIC NERVE NEUROPATHY WITH RETINAL GANGLION CELL

(RGC) AXON DEGENERATION FOLLOWED BY PROGRESSIVE RGC DEATH. UNDERSTANDING OF GENE REGULATION MECHANISMS THAT ARE ASSOCIATED WITH RGC AT NORMAL FUNCTION, UNDER DISEASE OR AFTER TREATMENT ARE ESSENTIAL FOR IDENTIFYING NOVEL THERAPEUTIC TARGETS AND INNOVATIVE AND EFFICIENT NEURAL REPAIR STRATEGIES. WE ARE TAKING ADVANTAGES OF NEWLY DEVELOPED GENETIC TOOLS TO ELUCIDATE THE COMPREHENSIVE GENE REGULATORY NETWORKS AND SERVE AS A BLUEPRINT FOR DEVELOPING NOVEL AND EFFECTIVE NEUROPROTECTANTS FOR GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2018183

NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ROSS POCHE, PHD, ENTITLED: (M2018022) REAWAKENING THE REGENERATIVE POTENTIAL OF MAMMALIAN MULLER GLIAL CELLS. INVESTIGATOR'S SUMMARY: THE MULLER GLIAL CELLS (MGC) WITHIN THE RETINA OF ZEBRAFISH AND OTHER NON-MAMMALIAN VERTEBRATES EXHIBIT THE REMARKABLE ABILITY TO REGENERATE DAMAGED RETINAL TISSUE WHILE MAMMALIAN MGC CANNOT. THIS PROJECT AIMS TO IDENTIFY THE CELLULAR AND MOLECULAR MECHANISMS FUNCTIONING AS AN INTRINSIC BLOCK TO MAMMALIAN MGC-MEDIATED RETINAL REGENERATION. WE WILL ALSO DETERMINE WHETHER BYPASSING THIS BLOCKING MECHANISM RESULTS IN MAMMALIAN RETINAL REGENERATION. SUCH A FINDING MAY LEAD TO NEW CLINICAL METHODS TO PREVENT OR REVERSE VISION LOSS DUE TO RETINAL INJURY OR DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018022

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CHICAGO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DIMITRA SKONDRA, MD, PHD, ENTITLED: (M2018042) ROLE OF HIGH FAT DIET AND GUT MICROBIOME IN

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD), THE LEADING CAUSE OF BLINDNESS IN ADULTS OVER 50, IS A COMPLEX DISEASE IN WHICH GENETIC RISK AND LIFESTYLE FACTORS LIKE DIET PLAY IMPORTANT ROLES BUT THE MECHANISMS BY WHICH THESE INTERACT REMAIN A MYSTERY BLOCKING THE DEVELOPMENT OF A CURE AND OF PREVENTION MEASURES. GUT MICROBIOME (MILLIONS OF MICROBES LIVING IN OUR GUT) PLAY A KEY ROLE IN HUMAN HEALTH AND DISEASES LIKE CANCER, ALLERGIES, DEMENTIA, ASTHMA AND ARE SIGNIFICANTLY AFFECTED BY DIET AND LIFESTYLE FACTORS. THE GOAL OF THIS INNOVATIVE PROPOSAL IS TO STUDY IF GUT MICROBES COULD BE THE MISSING LINK THAT CONNECTS DIET/LIFESTYLE FACTOR AND GENETIC RISK IN AMD INVESTIGATING HOW CHANGES IN THE MICROBES IN THE GUT BY DIET AFFECT AMD DEVELOPMENT AND CORRELATE WITH GENETIC RISK. THIS APPROACH WILL HELP UNCOVER MECHANISMS CAUSING AMD AND COULD PROVIDE A NEW BREAKTHROUGH INSIGHT INTO NEW TREATMENTS BY CHANGING OUR GUT MICROBIOME TO PREVENT THE LEADING CAUSE OF BLINDNESS IN OUR COMMUNITY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018042

SCHEDULE I, PART II, LINE 1, COLUMN (H):
NAME OF ORGANIZATION OR GOVERNMENT: THE SCHEPENS EYE RESEARCH INSTITUTE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MAGALI SAINT-GENIEZ, PHD, ENTITLED: (M2018064) INVESTIGATION OF A NEW TARGET IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: CENTRAL VISION LOSS HAS A PROFOUND IMPACT ON THE QUALITY OF LIFE AND FUNCTIONAL ABILITY OF AFFECTED PATIENTS. IN AGE-RELATED MACULAR DEGENERATION (AMD), SUCH LOSS IS ATTRIBUTED TO THE DYSFUNCTION OF A LAYER OF PIGMENTED CELLS CALLED THE RETINAL PIGMENT EPITHELIUM (RPE). THE OVERARCHING GOAL OF THIS PROJECT IS TO CHARACTERIZE THE ROLE OF A

PROTEIN, KNOWN TO REGULATE THE METABOLIC ACTIVITY IN CELLS, IN AMD PATHOGENESIS AND TO OFFER CRITICAL VALIDATIONS TO CURRENT CLINICAL DATA ASSOCIATING THIS PROTEIN TO THE MORE ADVANCED AND BLINDING FORM OF THE DISEASE, NEOVASCULAR AMD. RESULTS FROM THIS WORK ARE SIGNIFICANT NOT ONLY TO UNDERSTAND AMD PATHOGENESIS BUT ALSO TO OPEN UP NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF COMMON RETINAL DISEASES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018064

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JOHN HULLEMAN, PHD, ENTITLED: (M2018099) SMALL MOLECULE-BASED CONDITIONAL CONTROL OF INFLAMMATION AND COMPLEMENT ACTIVATION IN THE RETINA. INVESTIGATOR'S SUMMARY: THIS PROJECT SEEKS TO DETERMINE WHETHER DAMPENING INFLAMMATION USING A NEWLY DEVELOPED STRATEGY CAN PREVENT A PREVALENT, CURRENTLY UNTREATABLE INHERITED EYE DISEASE, STARGARDT DISEASE. OUR APPROACH IS UNIQUE IN THAT IT CAN BE 'TURNED ON' OR 'TURNED OFF' IN THE EYE WHEN NECESSARY, THEREBY MINIMIZING POTENTIAL DETRIMENTAL 'OFF TARGET' EFFECTS ASSOCIATED WITH CURRENT SIMILAR STRATEGIES. WE ANTICIPATE THAT THIS UNIQUE ASPECT OF OUR STRATEGY WILL MAKE IT MORE LIKELY TO BE EFFECTIVELY USED ULTIMATELY IN HUMANS WITH STARGARDT DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018099

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY XI-QIN DING, PHD, ENTITLED: (M2018107) THYROID HORMONE SIGNALING REGULATION OF RETINAL PIGMENT EPITHELIUM VIABILITY. INVESTIGATOR'S

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS AN EYE DISEASE MARKED BY PROGRESSIVE DEATH OF RETINAL PIGMENT EPITHELIUM CELLS (RPE) AND LIGHT-SENSITIVE NEURONS (PHOTORECEPTOR CELLS) IN THE CENTRAL (MACULAR) AREA OF THE RETINA. THE DISEASE IS THE LEADING CAUSE OF BLINDNESS IN THE ELDERLY, AND THERE ARE CURRENTLY NO CURATIVE TREATMENTS. THYROID HORMONE (TH) REGULATES CELL GROWTH, DIFFERENTIATION, AND METABOLISM, AND HAS RECENTLY BEEN ASSOCIATED WITH INCREASED RISK OF AMD. THIS STUDY WILL INVESTIGATE THE TH REGULATION OF RPE VIABILITY AND DETERMINE WHETHER SUPPRESSING TH SIGNALING PROTECTS RPE AGAINST OXIDATIVE DAMAGE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018107

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY WILLIAM SCOTT, PHD, ENTITLED: (M2018112) GENETIC FACTORS ACCELERATING PROGRESSION TO ADVANCED AMD. INVESTIGATOR'S SUMMARY: AGE RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF IRREVERSIBLE BLINDNESS IN OLDER ADULTS IN THE U.S. THE FACTORS THAT DETERMINE PROGRESSION FROM EARLY AMD (WITH LITTLE VISION LOSS) TO ADVANCED AMD (WITH MORE SEVERE VISION LOSS) ARE POORLY UNDERSTOOD. WE WILL USE DETAILED CLINICAL EXAMINATIONS OF THE EYE AND LARGE-SCALE GENETIC ANALYSIS TO IDENTIFY NEW GENETIC FACTORS THAT ARE ASSOCIATED WITH CHANGES IN THE EYE OVER TIME AND WITH DEVELOPMENT OF ADVANCED AMD. THE RESULTS OF THIS STUDY WILL IMPROVE OUR UNDERSTANDING OF THE AMD DISEASE PROCESS AND PROVIDE POTENTIAL AVENUES FOR DEVELOPMENT OF TARGETED THERAPIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018112

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS EYE AND EAR INFIRMARY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ROSARIO FERNANDEZ-GODINO, PHD, ENTITLED: (M2018115) THE ROLE OF COMPLEMENT RISK ALLELES AND TICK-OVER IN THE FORMATION OF SUB-RPE DEPOSITS AND RESPONSE TO ANTI-COMPLEMENT DRUGS IN AMD. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) AFFECTS MORE THAN 2 MILLION INDIVIDUALS IN THE US AND IT WILL REACH 3 MILLION BY 2020. CURRENT THERAPIES CAN IMPROVE VISION ONLY IN SOME PATIENTS WITH ADVANCED AMD; UNFORTUNATELY, THERE IS NO EFFECTIVE THERAPY THAT PREVENTS DISEASE PROGRESSION IN PATIENTS WITH EARLY DISEASE OR GENETIC PREDISPOSITION. MY AIM IS TO CREATE A CELL-BASED MODEL TO DISCOVER THE PRIMARY MECHANISMS ACTIVATED BY THE COMBINATION OF AGING AND GENETIC VARIANTS IN COMPLEMENT GENES IN PATIENTS WITH EARLY AMD; SO THAT DRUGS CAN BE DESIGNED TO STOP THESE MECHANISMS BEFORE THEY LEAD TO MAJOR DAMAGE AND LEGAL BLINDNESS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018115

NAME OF ORGANIZATION OR GOVERNMENT: BOSTON MEDICAL CENTER. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JI YI, PHD, ENTITLED: (M2018132) WIDE-FIELD VOLUMETRIC FLUORESCENCE ANGIOGRAPHY FOR SENSITIVE DETECTION OF RPE PERMEABILITY IN AMD. INVESTIGATOR'S SUMMARY: MACULAR DEGENERATION IS A DISEASE THAT DAMAGES THE CENTER OF THE EYE SIGHT AND CAN CAUSE BLINDNESS. THE DISEASE TAKES LONG TIME TO DEVELOP AND GRADUALLY PROGRESS TO BLINDING CONDITIONS. THE PROBLEM IS THAT WE DON'T HAVE PROPER TOOLS TO PREDICT WHEN A PATIENT'S EYE SIGHT WILL BE DAMAGED AND WHEN TO TREAT THE PATIENT BEFORE THE VISION GETS REALLY BAD. THIS PROJECT PLANS TO ADDRESS THIS PROBLEM BY DEVELOPING NEW TECHNIQUES TO DETECT THE DISEASE PROGRESSION. FOR MORE INFORMATION, VISIT THE

Name of the organization: BRIGHTFOCUS FOUNDATION | Employer identification number: 23-7337229

BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018132

NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YINGBIN FU, PHD, ENTITLED: (M2018142) A NOVEL TREATMENT STRATEGY TO TARGET THE UNDERLYING CAUSES OF BOTH THE WET AND DRY FORMS OF AMD. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A DISEASE THAT BLURS THE SHARP, CENTRAL VISION YOU NEED FOR EVERYDAY ACTIVITIES SUCH AS SEEING FACES, READING, SEWING, AND DRIVING. ADVANCED AMD CAN BE CLASSIFIED INTO THE DRY FORM (GRADUAL BREAKDOWN OF THE LIGHT-SENSITIVE CELLS IN THE MACULA) AND THE WET FORM (LEAKY BLOOD VESSELS GROWING UNDER THE RETINA). THE CURRENT TREATMENT FOR WET AMD IS SUBOPTIMAL WHILE THERE IS NO TREATMENT AVAILABLE FOR DRY AMD. WE PROPOSE TO DEVELOP A NOVEL AND EFFECTIVE TREATMENT FOR BOTH THE WET AND DRY FORMS OF AMD BY USING A NEW TARGET PROTEIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018142

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY KARL WAHLIN, PHD, ENTITLED: (M2018175) COMPLEMENT FACTOR H MUTANT PLURIPOTENT STEM CELLS TO MODEL EARLY ONSET MACULAR DEGENERATION AND THEIR APPLICATION IN DRUG DISCOVERY. INVESTIGATOR'S SUMMARY: MACULAR DEGENERATIVE DISEASE AFFECTS MILLIONS WORLDWIDE AND MODELS TO STUDY THE CONDITION IN HUMANS ARE GENERALLY LACKING. WE HAVE DEVELOPED HUMAN DISEASE BASED STEM CELL LINES THAT CAN BE READILY CONVERTED INTO RETINAL PIGMENT EPITHELIUM IN ORDER TO STUDY THE DISEASE PROCESS IN THE LABORATORY. UNIQUE TO THIS PROJECT, WE HAVE ALSO DESIGNED A FLUORESCENT PROTEIN REPORTER THAT WILL ALLOW US TO STUDY THE TEMPORAL DYNAMICS OF

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

RETINAL PIGMENT EPITHELIAL CELL DYSTROPHY, THUS ALLOWING THE SYSTEMATIC OPTIMIZATION OF DRUG SCREENING AIMED AT REDUCING PROTEIN DEPOSITS TYPICAL OF AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018175

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MARK KLEINMAN, MD, ENTITLED: (M2018193) DYSREGULATION OF THE ACETYLOME IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: WE ARE JUST BEGINNING TO GAIN SCIENTIFIC INSIGHT INTO THE POWER OF EPIGENETIC MODIFICATIONS ON GENOME-WIDE TRANSCRIPTION. IN THIS PROPOSAL, A HIGHLY SIGNIFICANT ROLE FOR HISTONE DEACETYLASE FUNCTION IN RETINAL PIGMENT EPITHELIAL CELL GENE EXPRESSION PROFILES AND CELL DEATH IN DRY AGE-RELATED MACULAR DEGENERATION WILL BE STUDIED. THESE DATA WILL PROVIDE IMPORTANT MOLECULAR INSIGHTS TO ENHANCE OUR KNOWLEDGE OF THE COMPLEX INTERSECTION OF AGING BIOLOGY, EPIGENETICS AND INFLAMMATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2018193

SCHEDULE I, PART II, LINE 1, COLUMN (H):

NAME OF ORGANIZATION OR GOVERNMENT: HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION. (H) PURPOSE OF GRANT: 2017 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP. THE HELEN KELLER PRIZE FOR VISION RESEARCH RECOGNIZES SIGNIFICANT ACCOMPLISHMENTS IN VISION RESEARCH, AND PROVIDES FUNDS FOR CONTINUANCE OF THOSE STUDIES.

NAME OF ORGANIZATION OR GOVERNMENT: HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION. (H) PURPOSE OF GRANT: 2018 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP. THE HELEN KELLER PRIZE FOR VISION RESEARCH

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

RECOGNIZES SIGNIFICANT ACCOMPLISHMENTS IN VISION RESEARCH, AND PROVIDES FUNDS FOR CONTINUANCE OF THOSE STUDIES.

NAME OF ORGANIZATION OR GOVERNMENT: DEAN MCGEE EYE INSTITUTE. (H) PURPOSE OF GRANT: 16TH INTERNATIONAL SYMPOSIUM ON RETINAL DEGENERATION 2018 MEETING - EXISTS TO FACILITATE KNOWLEDGE SHARING AMONGST RESEARCHERS IN THE AMD COMMUNITY AND OTHER RETINAL DISORDERS.

NAME OF ORGANIZATION OR GOVERNMENT: SCHEIE EYE INSTITUTE UNIVERSITY OF PENNSYLVANIA. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY BENJAMIN KIM, MD, ENTITLED: (CM2016971) THERAPEUTIC EVALUATION OF ALPHA LIPOIC ACID FOR GEOGRAPHIC ATROPHY. INVESTIGATOR'S SUMMARY: SUPPLEMENTAL FUNDING ON AWARD WITH NON-TECH ABSTRACT: THE BLINDING LESIONS OF THE GEOGRAPHIC ATROPHY (GA) FORM OF ADVANCED AGE-RELATED MACULAR DEGENERATION (AMD) ARE RESPONSIBLE FOR 20 PERCENT OF THE LEGAL BLINDNESS IN NORTH AMERICA. RESEARCH HAS SHOWN THAT OXIDATIVE STRESS AND IRON OVERLOAD AT THE RETINA ARE MAJOR CONTRIBUTORS TO THESE ATROPHIC LESIONS IN AMD, CONSISTING OF LOCALIZED AREAS OF DEAD CELLS. CURRENTLY THERE IS NO TREATMENT AVAILABLE; HOWEVER, THERE IS INTEREST IN A POTENT ANTIOXIDANT AND IRON CHELATOR CALLED ALPHA LIPOIC ACID. A CHELATING AGENT IS A SUBSTANCE WHOSE MOLECULES CAN FORM SEVERAL BONDS TO A SINGLE METAL ION, THUS SUPPRESSING ITS CHEMICAL ACTIVITY. ALPHA LIPOIC ACID IS FOUND IN MANY FOOD SOURCES, INCLUDING SPINACH, BROCCOLI, AND POTATOES; IT ALSO IS MANUFACTURED FOR USE AS A SUPPLEMENT. THROUGH A PHASE II PILOT CLINICAL TRIAL, WE ARE TESTING ALPHA LIPOIC ACID AS A TREATMENT FOR GA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CM2016971

SCHEDULE R (Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.

▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I **Identification of Disregarded Entities.** Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
NATIONAL DEVELOPMENT, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	PROPERTY RENTAL AND MANAGEMENT	MARYLAND	568,259.	4,415,046.	BRIGHTFOCUS FOUNDATION
AMERICAN HEALTH ASSISTANCE, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	OWNER OF BRIGHTFOCUS HEADQUARTERS	MARYLAND	0.	3,815,377.	BRIGHTFOCUS FOUNDATION

Part II **Identification of Related Tax-Exempt Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity? Yes	(g) No

COPY

Part III **Identification of Related Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations? Yes	(h) No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner? Yes	(j) No	(k) Percentage ownership

Part IV **Identification of Related Organizations Taxable as a Corporation or Trust.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity? Yes	(i) No

COPY

Part V Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

			Yes	No
1	During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?			
a	Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity	1a		
b	Gift, grant, or capital contribution to related organization(s)	1b		
c	Gift, grant, or capital contribution from related organization(s)	1c		
d	Loans or loan guarantees to or for related organization(s)	1d		
e	Loans or loan guarantees by related organization(s)	1e		
f	Dividends from related organization(s)	1f		
g	Sale of assets to related organization(s)	1g		
h	Purchase of assets from related organization(s)	1h		
i	Exchange of assets with related organization(s)	1i		
j	Lease of facilities, equipment, or other assets to related organization(s)	1j		
k	Lease of facilities, equipment, or other assets from related organization(s)	1k		
l	Performance of services or membership or fundraising solicitations for related organization(s)	1l		
m	Performance of services or membership or fundraising solicitations by related organization(s)	1m		
n	Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)	1n		
o	Sharing of paid employees with related organization(s)	1o		
p	Reimbursement paid to related organization(s) for expenses	1p		
q	Reimbursement paid by related organization(s) for expenses	1q		
r	Other transfer of cash or property to related organization(s)	1r		
s	Other transfer of cash or property from related organization(s)	1s		

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

	(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				

COPY

Part VI **Unrelated Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(e) Are all partners sec. 501(c)(3) orgs.? Yes	(e) No	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations? Yes	(h) No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner? Yes	(j) No	(k) Percentage ownership

COPY

Part VII Supplemental Information.

Provide additional information for responses to questions on Schedule R. See instructions.